<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antibiotics for hospital‐acquired pneumonia in neonates and children - Korang, SK - 2021 | Cochrane Library</title> <meta content="Antibiotics for hospital‐acquired pneumonia in neonates and children - Korang, SK - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013864.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antibiotics for hospital‐acquired pneumonia in neonates and children - Korang, SK - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013864.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013864.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Antibiotics for hospital‐acquired pneumonia in neonates and children" name="citation_title"/> <meta content="Steven Kwasi Korang" name="citation_author"/> <meta content="The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="steven.korang@ctu.dk" name="citation_author_email"/> <meta content="Chiara Nava" name="citation_author"/> <meta content='Ospedale "A. Manzoni"' name="citation_author_institution"/> <meta content="Sutharshini Punniyamoorthy Mohana" name="citation_author"/> <meta content="Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Ulrikka Nygaard" name="citation_author"/> <meta content="Copenhagen University Hospital, Rigshospitalet" name="citation_author_institution"/> <meta content="Janus C Jakobsen" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD013864.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/11/02" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013864.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013864.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013864.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Anti-Bacterial Agents; Hospitals; *Pneumonia [drug therapy]; Quality of Life; Randomized Controlled Trials as Topic; Vancomycin" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013864.pub2&amp;doi=10.1002/14651858.CD013864.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="bzu3XIhG";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013864\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013864\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013864\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013864\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","th","ms","ja","hr","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013864.pub2",title:"Antibiotics for hospital\\u2010acquired pneumonia in neonates and children",firstPublishedDate:"Nov 2, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Acute Respiratory Infections Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=bzu3XIhG&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013864.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013864.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013864.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013864.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013864.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013864.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013864.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013864.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013864.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013864.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5691 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013864.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/full#CD013864-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/full#CD013864-sec-0093"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/full#CD013864-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/full#CD013864-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/full#CD013864-sec-0019"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/full#CD013864-sec-0020"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/full#CD013864-sec-0049"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/full#CD013864-sec-0083"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/appendices#CD013864-sec-0098"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/table_n/CD013864StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/table_n/CD013864StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antibiotics for hospital‐acquired pneumonia in neonates and children</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/information#CD013864-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Steven Kwasi Korang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/information#CD013864-cr-0005">Chiara Nava</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/information#CD013864-cr-0006">Sutharshini Punniyamoorthy Mohana</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/information#CD013864-cr-0007">Ulrikka Nygaard</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013864.pub2/information#CD013864-cr-0008">Janus C Jakobsen</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/information/en#CD013864-sec-0113">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 02 November 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013864.pub2">https://doi.org/10.1002/14651858.CD013864.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013864-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013864-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013864-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013864-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013864-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD013864-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013864-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013864-abs-0001" lang="en"> <section id="CD013864-sec-0001"> <h3 class="title" id="CD013864-sec-0001">Background</h3> <p>Hospital‐acquired pneumonia is one of the most common hospital‐acquired infections in children worldwide. Most of our understanding of hospital‐acquired pneumonia in children is derived from adult studies. To our knowledge, no systematic review with meta‐analysis has assessed the benefits and harms of different antibiotic regimens in neonates and children with hospital‐acquired pneumonia. </p> </section> <section id="CD013864-sec-0002"> <h3 class="title" id="CD013864-sec-0002">Objectives</h3> <p>To assess the beneficial and harmful effects of different antibiotic regimens for hospital‐acquired pneumonia in neonates and children. </p> </section> <section id="CD013864-sec-0003"> <h3 class="title" id="CD013864-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, three other databases, and two trial registers to February 2021, together with reference checking, citation searching, and contact with study authors to identify additional studies. </p> </section> <section id="CD013864-sec-0004"> <h3 class="title" id="CD013864-sec-0004">Selection criteria</h3> <p>We included randomised clinical trials comparing one antibiotic regimen with any other antibiotic regimen for hospital‐acquired pneumonia in neonates and children. </p> </section> <section id="CD013864-sec-0005"> <h3 class="title" id="CD013864-sec-0005">Data collection and analysis</h3> <p>Three review authors independently assessed studies for inclusion, extracted data, and assessed risk of bias. We assessed the certainty of the evidence using the GRADE approach. Our primary outcomes were all‐cause mortality and serious adverse events; our secondary outcomes were health‐related quality of life, pneumonia‐related mortality, non‐serious adverse events, and treatment failure. Our primary time point of interest was at maximum follow‐up. </p> </section> <section id="CD013864-sec-0006"> <h3 class="title" id="CD013864-sec-0006">Main results</h3> <p>We included four randomised clinical trials (84 participants). We assessed all trials as having high risk of bias. </p> <p>We did not conduct any meta‐analyses, as the included trials did not compare similar antibiotic regimens. </p> <p>Each of the four trials assessed a different comparison, as follows: cefepime versus ceftazidime; linezolid versus vancomycin; meropenem versus cefotaxime; and ceftobiprole versus cephalosporin. </p> <p>Only one trial reported our primary outcomes of all‐cause mortality and serious adverse events. Three trials reported our secondary outcome of treatment failure. Two trials primarily included community‐acquired pneumonia and hospitalised children with bacterial infections, hence the children with hospital‐acquired pneumonia constituted subgroups of the total sample sizes. </p> <p>Where outcomes were reported, the certainty of the evidence was very low for each of the comparisons. We are unable to draw meaningful conclusions from the numerical results. </p> <p>None of the included trials assessed health‐related quality of life, pneumonia‐related mortality, or non‐serious adverse events. </p> </section> <section id="CD013864-sec-0007"> <h3 class="title" id="CD013864-sec-0007">Authors' conclusions</h3> <p>The relative beneficial and harmful effects of different antibiotic regimens remain unclear due to the very low certainty of the available evidence. The current evidence is insufficient to support any antibiotic regimen being superior to another. Randomised clinical trials assessing different antibiotic regimens for hospital‐acquired pneumonia in children and neonates are warranted. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013864-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013864-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013864-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013864-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013864-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013864-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013864-abs-0010">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013864-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013864-abs-0016">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013864-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD013864-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013864-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013864-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013864-abs-0002" lang="en"> <h3>Antibiotics for hospital‐acquired pneumonia in newborns and children</h3> <p><b>Review question</b> </p> <p>Which antibiotic regimen is safer and more effective in treating neonates (newborns) and children with hospital‐acquired pneumonia? </p> <p><b>Background</b> </p> <p>Hospital‐acquired pneumonia is an inflammation of the tissue of one or both lungs caused by an infection that occurs during a hospital stay (i.e. 48 hours or more after hospital admission). It is one of the most common hospital‐acquired infections in children worldwide, and is associated with a high death rate. Most of our understanding of hospital‐acquired pneumonia in children is drawn from adult studies. To our knowledge this is the first review with meta‐analysis that assesses the benefits and harms of different antibiotic regimens in newborns and children with hospital‐acquired pneumonia. </p> <p><b>Search date</b> </p> <p>The evidence is current to February 2021.</p> <p><b>Study characteristics</b> </p> <p>We included four trials randomising 84 children with hospital‐acquired pneumonia to different antibiotic regimens. Three trials were multicentre trials from the USA, Latin America, Europe, and South Africa. The South African trial included one site in Malaysia. Each of the four included trials compared different antibiotic regimens, as follows: cefepime versus ceftazidime; linezolid versus vancomycin; meropenem versus cefotaxime; and ceftobiprole versus cephalosporin. </p> <p><b>Study funding sources</b> </p> <p>Three trials were funded by pharmaceutical companies (Zeneca Pharmaceuticals, Pharmacia Corp, and Basilea Pharmaceutica International Ltd.), indicating a possible risk of bias related to a vested interest risk. </p> <p><b>Key results</b> </p> <p>Each of the four included trials compared different antibiotic regimens, as follows: cefepime versus ceftazidime; linezolid versus vancomycin; meropenem versus cefotaxime; and ceftobiprole versus cephalosporin. </p> <p>Only one trial reported our primary outcomes of death from all causes and serious adverse events (major complications). Three trials reported our secondary outcome of treatment failure. Two trials primarily included community‐acquired pneumonia and hospitalised children with bacterial infections, hence the children with hospital‐acquired pneumonia constituted only subgroups of the total study populations. </p> <p>Where outcomes were reported, the certainty of the evidence was very low for each of the comparisons. We were unable to draw any meaningful conclusions from the numerical results. </p> <p>None of the included trials assessed health‐related quality of life, pneumonia‐related death, or non‐serious adverse events (minor complications). </p> <p><b>Conclusions</b> </p> <p>The available evidence does not suggest that one antibiotic regimen is safer and more effective than another in treating newborns and children with hospital‐acquired pneumonia. Further research is needed. </p> <p><b>Certainty of the evidence</b> </p> <p>The certainty of evidence is very low. All four included trials had high risk of bias (i.e. the studies were designed in such a way that the results may have been skewed). In addition, the included trials involved few participants, which is likely to have led to inaccurate results. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013864-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013864-sec-0093"></div> <h3 class="title" id="CD013864-sec-0094">Implications for practice</h3> <section id="CD013864-sec-0094"> <p>Based on the currently available evidence, we were unable to confirm or reject whether one antibiotic regimen is superior to another. </p> </section> <h3 class="title" id="CD013864-sec-0095">Implications for research</h3> <section id="CD013864-sec-0095"> <p>Randomised clinical trials are needed to assess the effects of different antibiotic regimens for hospital‐acquired pneumonia. Such trials should: </p> <p> <ol id="CD013864-list-0018"> <li> <p>randomise a sufficient number of participants to demonstrate reliable results;</p> </li> <li> <p>assess treatment failure, all‐cause mortality, and serious adverse events; and</p> </li> <li> <p>be conducted such that there is a low risk of bias.</p> </li> </ol> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013864-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013864-sec-0008"></div> <div class="table" id="CD013864-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Cefepime compared with ceftazidime for hospital‐acquired pneumonia in neonates and children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cefepime compared with ceftazidime for hospital‐acquired pneumonia in neonates and children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates and children with hospital‐acquired pneumonia </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> cefepime </p> <p><b>Comparison:</b> ceftazidime </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ceftazidime</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Cefepime</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Maximum follow‐up</p> <p>(Time point was not described.)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b><br/>(2 to 510) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.14</b> (0.01 to 2.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 3262 (RR 0.80, α 0.033, β 0.20, Pc 20%)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Maximum follow‐up</p> <p>(Time point was not described.)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b><br/>(2 to 510) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.14</b> (0.01 to 2.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 3262 (RR 0.80, α 0.033, β 0.20, Pc 20%)</p> <p>Serious adverse events were deaths.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>Maximum follow‐up</p> <p>(Time point was not described.)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b><br/>(60 to 656) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b> (0.15 to 1.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 1272 (RR 0.80, α 0.033, β 0.20, Pc 40%)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p>Maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonia‐related mortality</b> </p> <p>Maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐serious adverse events</b> </p> <p>Maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OIS</b> : optimal information size; <b>RR:</b> risk ratio; <b>Pc:</b> percentage in control group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by 1 level for study limitations due to serious risk of bias, and two levels for imprecision due to very small information size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013864-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Linezolid compared with vancomycin for hospital‐acquired pneumonia in neonates and children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Linezolid compared with vancomycin for hospital‐acquired pneumonia in neonates and children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates and children with hospital‐acquired pneumonia </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> linezolid </p> <p><b>Comparison:</b> vancomycin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vancomycin</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Linezolid</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Maximum follow‐up</p> <p>(up to 35 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Maximum follow‐up</p> <p>(up to 35 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>Maximum follow‐up</p> <p>(up to 35 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>154 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>315 per 1000</b><br/>(75 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.05</b> (0.49 to 8.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 4438 (RR 0.80, α 0.033, β 0.20, Pc 15.4%)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p>Maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonia‐related mortality</b> </p> <p>Maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐serious adverse events</b> </p> <p>Maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OIS</b> : optimal information size; <b>RR:</b> risk ratio; <b>Pc:</b> percentage in control group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by 1 level for study limitations due to serious risk of bias, and 2 levels for imprecision due to very small information size. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013864-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013864-sec-0009"></div> <section id="CD013864-sec-0010"> <h3 class="title" id="CD013864-sec-0010">Description of the condition</h3> <p>Hospital‐acquired pneumonia (also known as nosocomial pneumonia) is defined as pneumonia that occurs 48 hours or more after hospital admission (<a href="./references#CD013864-bbs2-0054" title="EcclesS , PincusC , HigginsB , WoodheadM , Guideline Development Group. Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance. BMJ (Clinical Research Ed.)2014;349:g6722.">Eccles 2014</a>; <a href="./references#CD013864-bbs2-0083" title="KalilAC , MeterskyML , KlompasM , MuscedereJ , SweeneyDA , PalmerLB , et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America2016;63(5):61-111.">Kalil 2016</a>; <a href="./references#CD013864-bbs2-0129" title="TorresA , NiedermanMS , ChastreJ , EwigS , Fernandez-VandellosP , HanbergerH , et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). European Respiratory Journal2017;50(3):1-26.">Torres 2017</a>). </p> <section id="CD013864-sec-0011"> <h4 class="title">Epidemiology</h4> <p>Hospital‐acquired infection is a serious complication of hospitalisation worldwide in adults and children (<a href="./references#CD013864-bbs2-0107" title="PolinRA , DensonS , BradyMT , Committee on Fetus and Newborn, Committee on Infectious Diseases. Epidemiology and diagnosis of health care-associated infections in the NICU. Pediatrics2012;129(4):e1104-9.">Polin 2012</a>; <a href="./references#CD013864-bbs2-0141" title="ZinggW , HopkinsS , Gayet-AgeronA , HolmesA , SharlandM , SuetensC , et al. Health-care-associated infections in neonates, children, and adolescents: an analysis of paediatric data from the European Centre for Disease Prevention and Control point-prevalence survey. Lancet Infectious Diseases2017;17(4):381-9.">Zingg 2017</a>). The incidence of hospital‐acquired infections is between 0.17% and 36% of hospitalised paediatric patients (<a href="./references#CD013864-bbs2-0107" title="PolinRA , DensonS , BradyMT , Committee on Fetus and Newborn, Committee on Infectious Diseases. Epidemiology and diagnosis of health care-associated infections in the NICU. Pediatrics2012;129(4):e1104-9.">Polin 2012</a>; <a href="./references#CD013864-bbs2-0133" title="VijayG , MandalA , SankarJ , KapilA , LodhaR , KabraSK . Ventilator associated pneumonia in pediatric intensive care unit: incidence, risk factors and etiological agents. Indian Journal of Pediatrics2018;85(10):861-6.">Vijay 2018</a>). Variations in incidence may be due to differences in diagnostic criteria as well as differences in local risk factors for the development of hospital‐acquired infections (<a href="./references#CD013864-bbs2-0107" title="PolinRA , DensonS , BradyMT , Committee on Fetus and Newborn, Committee on Infectious Diseases. Epidemiology and diagnosis of health care-associated infections in the NICU. Pediatrics2012;129(4):e1104-9.">Polin 2012</a>; <a href="./references#CD013864-bbs2-0133" title="VijayG , MandalA , SankarJ , KapilA , LodhaR , KabraSK . Ventilator associated pneumonia in pediatric intensive care unit: incidence, risk factors and etiological agents. Indian Journal of Pediatrics2018;85(10):861-6.">Vijay 2018</a>). The highest incidences are seen in neonatal intensive care units (NICUs) and paediatric intensive care units (PICUs) (<a href="./references#CD013864-bbs2-0077" title="IosifidisE , PitsavaG , RoilidesE . Ventilator-associated pneumonia in neonates and children: a systematic analysis of diagnostic methods and prevention. Future Microbiology2018;13:1431-46.">Iosifidis 2018</a>; <a href="./references#CD013864-bbs2-0107" title="PolinRA , DensonS , BradyMT , Committee on Fetus and Newborn, Committee on Infectious Diseases. Epidemiology and diagnosis of health care-associated infections in the NICU. Pediatrics2012;129(4):e1104-9.">Polin 2012</a>; <a href="./references#CD013864-bbs2-0123" title="SteinF , TrevinoR . Nosocomial infections in the pediatric intensive care unit. Pediatric Clinics of North America1994;41(6):1245-57.">Stein 1994</a>; <a href="./references#CD013864-bbs2-0141" title="ZinggW , HopkinsS , Gayet-AgeronA , HolmesA , SharlandM , SuetensC , et al. Health-care-associated infections in neonates, children, and adolescents: an analysis of paediatric data from the European Centre for Disease Prevention and Control point-prevalence survey. Lancet Infectious Diseases2017;17(4):381-9.">Zingg 2017</a>). European studies suggest that the incidence of hospital‐acquired infections is higher in paediatric surgical wards (17%) compared with general paediatrics wards (2.5%) (<a href="./references#CD013864-bbs2-0092" title="LiK , LiX , SiW , CuiY , XiaH , SunX , et al. Preoperative and operation-related risk factors for postoperative nosocomial infections in pediatric patients: a retrospective cohort study. PLOS ONE2019;14(12):e0225607.">Li 2019</a>). </p> <p>Hospital‐acquired pneumonia is one of the most common hospital‐acquired infections in children worldwide (<a href="./references#CD013864-bbs2-0036" title="AlvaresPA , ArnoniMV , da SilvaCB , SafadiMAP , MimicaMJ . Hospital-acquired infections in children: a Latin American tertiary teaching hospital 5-year experience. Pediatric Infectious Disease Journal2019;38(1):e12.">Alvares 2019</a>). Hospital‐acquired pneumonia in neonates and children accounts for 6.8% to 32.3% of all hospital‐acquired infections (<a href="./references#CD013864-bbs2-0107" title="PolinRA , DensonS , BradyMT , Committee on Fetus and Newborn, Committee on Infectious Diseases. Epidemiology and diagnosis of health care-associated infections in the NICU. Pediatrics2012;129(4):e1104-9.">Polin 2012</a>; <a href="./references#CD013864-bbs2-0123" title="SteinF , TrevinoR . Nosocomial infections in the pediatric intensive care unit. Pediatric Clinics of North America1994;41(6):1245-57.">Stein 1994</a>; <a href="./references#CD013864-bbs2-0141" title="ZinggW , HopkinsS , Gayet-AgeronA , HolmesA , SharlandM , SuetensC , et al. Health-care-associated infections in neonates, children, and adolescents: an analysis of paediatric data from the European Centre for Disease Prevention and Control point-prevalence survey. Lancet Infectious Diseases2017;17(4):381-9.">Zingg 2017</a>). It is therefore a frequent cause of hospital‐acquired infection in patients in the NICU or PICU, only surpassed by catheter‐associated bloodstream infections (<a href="./references#CD013864-bbs2-0040" title="BighamMT , AmatoR , BondurrantP , FridrikssonJ , KrawczeskiCD , RaakeJ , et al. Ventilator-associated pneumonia in the pediatric intensive care unit: characterizing the problem and implementing a sustainable solution. Journal of Pediatrics2009;154(4):582-7.">Bigham 2009</a>; <a href="./references#CD013864-bbs2-0044" title="CernadaM , AguarM , BrugadaM , GutiérrezA , LópezJL , CastellM , et al. Ventilator-associated pneumonia in newborn infants diagnosed with an invasive bronchoalveolar lavage technique: a prospective observational study. Pediatric Critical Care Medicine2013;14(1):55-61.">Cernada 2013</a>; <a href="./references#CD013864-bbs2-0107" title="PolinRA , DensonS , BradyMT , Committee on Fetus and Newborn, Committee on Infectious Diseases. Epidemiology and diagnosis of health care-associated infections in the NICU. Pediatrics2012;129(4):e1104-9.">Polin 2012</a>; <a href="./references#CD013864-bbs2-0111" title="RichardsMJ , EdwardsJR , CulverDH , GaynesRP . Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. Pediatrics1999;103(4):e39.">Richards 1999</a>; <a href="./references#CD013864-bbs2-0141" title="ZinggW , HopkinsS , Gayet-AgeronA , HolmesA , SharlandM , SuetensC , et al. Health-care-associated infections in neonates, children, and adolescents: an analysis of paediatric data from the European Centre for Disease Prevention and Control point-prevalence survey. Lancet Infectious Diseases2017;17(4):381-9.">Zingg 2017</a>). The incidence is particularly high amongst premature neonates or neonates with low birth weight (<a href="./references#CD013864-bbs2-0037" title="ApisarnthanarakA , Holzmann-PazgalG , HamvasA , OlsenMA , FraserVJ . Ventilator-associated pneumonia in extremely preterm neonates in a neonatal intensive care unit: characteristics, risk factors, and outcomes. Pediatrics2003;112(6 Pt 1):1283-9.">Apisarnthanarak 2003</a>; <a href="./references#CD013864-bbs2-0126" title="TanB , ZhangF , ZhangX , HuangYL , GaoYS , LiuX , et al. Risk factors for ventilator-associated pneumonia in the neonatal intensive care unit: a meta-analysis of observational studies. European Journal of Pediatrics2014;173(4):427-34.">Tan 2014</a>). Paediatric hospital‐acquired pneumonia has been shown to be associated with increased mortality (<a href="./references#CD013864-bbs2-0040" title="BighamMT , AmatoR , BondurrantP , FridrikssonJ , KrawczeskiCD , RaakeJ , et al. Ventilator-associated pneumonia in the pediatric intensive care unit: characterizing the problem and implementing a sustainable solution. Journal of Pediatrics2009;154(4):582-7.">Bigham 2009</a>; <a href="./references#CD013864-bbs2-0077" title="IosifidisE , PitsavaG , RoilidesE . Ventilator-associated pneumonia in neonates and children: a systematic analysis of diagnostic methods and prevention. Future Microbiology2018;13:1431-46.">Iosifidis 2018</a>). Hospital‐acquired pneumonia is associated with even higher mortality and morbidity in preterm neonates (<a href="./references#CD013864-bbs2-0037" title="ApisarnthanarakA , Holzmann-PazgalG , HamvasA , OlsenMA , FraserVJ . Ventilator-associated pneumonia in extremely preterm neonates in a neonatal intensive care unit: characteristics, risk factors, and outcomes. Pediatrics2003;112(6 Pt 1):1283-9.">Apisarnthanarak 2003</a>). </p> <p>The vast majority of hospital‐acquired pneumonia is ventilator‐associated pneumonia, a subtype of hospital‐acquired pneumonia. Ventilator‐associated pneumonia is defined as "pneumonia that occurs 48 hours or more after endotracheal intubation" (<a href="./references#CD013864-bbs2-0044" title="CernadaM , AguarM , BrugadaM , GutiérrezA , LópezJL , CastellM , et al. Ventilator-associated pneumonia in newborn infants diagnosed with an invasive bronchoalveolar lavage technique: a prospective observational study. Pediatric Critical Care Medicine2013;14(1):55-61.">Cernada 2013</a>; <a href="./references#CD013864-bbs2-0077" title="IosifidisE , PitsavaG , RoilidesE . Ventilator-associated pneumonia in neonates and children: a systematic analysis of diagnostic methods and prevention. Future Microbiology2018;13:1431-46.">Iosifidis 2018</a>; <a href="./references#CD013864-bbs2-0082" title="JoramN , deSaint BlanquatL , StammD , LaunayE , Gras-Le GuenC . Healthcare-associated infection prevention in pediatric intensive care units: a review. European Journal of Clinical Microbiology &amp; Infectious Diseases: official publication of the European Society of Clinical Microbiology2012;31(10):2481-90.">Joram 2012</a>; <a href="./references#CD013864-bbs2-0083" title="KalilAC , MeterskyML , KlompasM , MuscedereJ , SweeneyDA , PalmerLB , et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America2016;63(5):61-111.">Kalil 2016</a>; <a href="./references#CD013864-bbs2-0129" title="TorresA , NiedermanMS , ChastreJ , EwigS , Fernandez-VandellosP , HanbergerH , et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). European Respiratory Journal2017;50(3):1-26.">Torres 2017</a>). The incidence of ventilator‐associated pneumonia is reported to be 2.9 to 11.6 cases per 1000 ventilator days (<a href="./references#CD013864-bbs2-0051" title="deNeefM , BakkerL , DijkstraS , Raymakers-JanssenP , VileitoA , IstaE . Effectiveness of a ventilator care bundle to prevent ventilator-associated pneumonia at the PICU: a systematic review and meta-analysis. Pediatric Critical Care Medicine2019;20(5):474-80.">de Neef 2019</a>; <a href="./references#CD013864-bbs2-0080" title="JarvisWR , EdwardsJR , CulverDH , HughesJM , HoranT , EmoriTG , et al. Nosocomial infection rates in adult and pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. American Journal of Medicine1991;91(3B):185-91.">Jarvis 1991</a>; <a href="./references#CD013864-bbs2-0082" title="JoramN , deSaint BlanquatL , StammD , LaunayE , Gras-Le GuenC . Healthcare-associated infection prevention in pediatric intensive care units: a review. European Journal of Clinical Microbiology &amp; Infectious Diseases: official publication of the European Society of Clinical Microbiology2012;31(10):2481-90.">Joram 2012</a>). </p> <p>Even though most research is focused on ventilator‐associated pneumonia, non‐ventilatory hospital‐acquired pneumonia has similar, or even higher mortality rates and financial costs than ventilator‐associated pneumonia, whilst its incidence could be underestimated (<a href="./references#CD013864-bbs2-0049" title="DavisJ , FinleyE . The breadth of hospital-acquired pneumonia: nonventilated versus ventilated patients in Pennsylvania. Pennsylvania Patient Safety Advisory2012;9(3):99-105.">Davis 2012</a>; <a href="./references#CD013864-bbs2-0061" title="GiulianoKK , BakerD , QuinnB . The epidemiology of nonventilator hospital-acquired pneumonia in the United States. American Journal of Infection Control2018;46(3):322-7.">Giuliano 2018</a>). </p> </section> <section id="CD013864-sec-0012"> <h4 class="title">Risk factors</h4> <p>Risk factors for hospital‐acquired pneumonia are prolonged hospitalisation, mechanical ventilation, serious underlying illnesses (e.g. lung disease, immune deficiency), bloodstream infections, recent antimicrobial therapy, genetic syndromes, immunosuppression, use of steroids, prematurity, low birth weight, reintubation or self‐extubation, and bronchoscopy (<a href="./references#CD013864-bbs2-0034" title="AelamiMH , LotfiM , ZinggW . Ventilator-associated pneumonia in neonates, infants and children. Antimicrobial Resistance and Infection Control2014;3(1):30.">Aelami 2014</a>; <a href="./references#CD013864-bbs2-0093" title="LiuB , LiSQ , ZhangSM , XuP , ZhangX , ZhangYH , et al. Risk factors of ventilator-associated pneumonia in pediatric intensive care unit: a systematic review and meta-analysis. Journal of Thoracic Disease2013;5(4):525-53.">Liu 2013</a>; <a href="./references#CD013864-bbs2-0123" title="SteinF , TrevinoR . Nosocomial infections in the pediatric intensive care unit. Pediatric Clinics of North America1994;41(6):1245-57.">Stein 1994</a>). Newborns, preterms, and infants are especially prone to infections, due to a developmental deficiency in the innate, adaptive immune systems, usage of endotracheal and orogastric tubes, exposure to broad‐spectrum antibiotic agents, and parenteral nutrition (<a href="./references#CD013864-bbs2-0034" title="AelamiMH , LotfiM , ZinggW . Ventilator-associated pneumonia in neonates, infants and children. Antimicrobial Resistance and Infection Control2014;3(1):30.">Aelami 2014</a>; <a href="./references#CD013864-bbs2-0107" title="PolinRA , DensonS , BradyMT , Committee on Fetus and Newborn, Committee on Infectious Diseases. Epidemiology and diagnosis of health care-associated infections in the NICU. Pediatrics2012;129(4):e1104-9.">Polin 2012</a>; <a href="./references#CD013864-bbs2-0126" title="TanB , ZhangF , ZhangX , HuangYL , GaoYS , LiuX , et al. Risk factors for ventilator-associated pneumonia in the neonatal intensive care unit: a meta-analysis of observational studies. European Journal of Pediatrics2014;173(4):427-34.">Tan 2014</a>). This broad range of risk factors increases the risk of hospital‐acquired pneumonia; however, they are associated with different kinds of pathogens (<a href="./references#CD013864-bbs2-0100" title="MouraniPM , SontagMK . Ventilator-associated pneumonia in critically ill children: a new paradigm. Pediatric Clinics of North America2017;64(5):1039-56.">Mourani 2017</a>; <a href="./references#CD013864-bbs2-0107" title="PolinRA , DensonS , BradyMT , Committee on Fetus and Newborn, Committee on Infectious Diseases. Epidemiology and diagnosis of health care-associated infections in the NICU. Pediatrics2012;129(4):e1104-9.">Polin 2012</a>), therefore one antibiotic regimen for all patients might not be warranted. </p> <p>The onset of ventilator‐associated pneumonia is also a risk factor associated with specific pathogens and prognosis (<a href="./references#CD013864-bbs2-0055" title="EwigS , TorresA , El-EbiaryM , FabregasN , HernandezC , GonzalezJ , et al. Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury. Incidence, risk factors, and association with ventilator-associated pneumonia. American Journal of Respiratory and Critical Care Medicine1999;159(1):188-98. [PMID: 9872838]">Ewig 1999</a>; <a href="./references#CD013864-bbs2-0083" title="KalilAC , MeterskyML , KlompasM , MuscedereJ , SweeneyDA , PalmerLB , et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America2016;63(5):61-111.">Kalil 2016</a>; <a href="./references#CD013864-bbs2-0112" title="SafdarN , CrnichCJ , MakiDG . The pathogenesis of ventilator-associated pneumonia: its relevance to developing effective strategies for prevention. Respiratory Care2005;50(6):725-39; discussion 739-41.">Safdar 2005</a>). Early‐onset ventilator‐associated pneumonia and late‐onset ventilator‐associated pneumonia are distinguished by whether the ventilator‐associated pneumonia occurs before or after the first four days of hospitalisation (<a href="./references#CD013864-bbs2-0090" title="LangerM , CigadaM , MandelliM , MosconiP , TognoniG . Early onset pneumonia: a multicenter study in intensive care units. Intensive Care Medicine1987;13(5):342-6.">Langer 1987</a>). Early‐onset ventilator‐associated pneumonia is associated with a better prognosis than late‐onset ventilator‐associated pneumonia (<a href="./references#CD013864-bbs2-0083" title="KalilAC , MeterskyML , KlompasM , MuscedereJ , SweeneyDA , PalmerLB , et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America2016;63(5):61-111.">Kalil 2016</a>; <a href="./references#CD013864-bbs2-0112" title="SafdarN , CrnichCJ , MakiDG . The pathogenesis of ventilator-associated pneumonia: its relevance to developing effective strategies for prevention. Respiratory Care2005;50(6):725-39; discussion 739-41.">Safdar 2005</a>). </p> </section> <section id="CD013864-sec-0013"> <h4 class="title">Pathophysiology</h4> <p>Hospital‐acquired pneumonia is most often caused by aspiration of bacteria from the pharynx, oral cavity, or the upper gastrointestinal tract (<a href="./references#CD013864-bbs2-0107" title="PolinRA , DensonS , BradyMT , Committee on Fetus and Newborn, Committee on Infectious Diseases. Epidemiology and diagnosis of health care-associated infections in the NICU. Pediatrics2012;129(4):e1104-9.">Polin 2012</a>). The increased risk of ventilator‐associated pneumonia after intubation is caused by endotracheal tubes bypassing the initial host barrier defence mechanisms (<a href="./references#CD013864-bbs2-0107" title="PolinRA , DensonS , BradyMT , Committee on Fetus and Newborn, Committee on Infectious Diseases. Epidemiology and diagnosis of health care-associated infections in the NICU. Pediatrics2012;129(4):e1104-9.">Polin 2012</a>). In the absence of the endotracheal tube as a direct portal of entry for pathogens, non‐ventilatory hospital‐acquired pneumonia could be caused by the contiguous spread of a primary infection at a distant site (<a href="./references#CD013864-bbs2-0107" title="PolinRA , DensonS , BradyMT , Committee on Fetus and Newborn, Committee on Infectious Diseases. Epidemiology and diagnosis of health care-associated infections in the NICU. Pediatrics2012;129(4):e1104-9.">Polin 2012</a>), or by specific conditions of susceptibility of the patient. For example, hospital‐acquired pneumonia is more frequent in patients who are subjected to several emergency procedures, or who have skin and mucous lesions, which cause a disruption of natural membrane defences, with an increased risk of the infection spreading. Hence, there is a higher rate of hospital‐acquired pneumonia in paediatric patients hospitalised for an injury including the head and neck, and those with firearm or pulmonary injuries (<a href="./references#CD013864-bbs2-0048" title="CutlerGJ , KharbandaAB , NowakJ , OrtegaHW . Injury region and risk of hospital-acquired pneumonia among pediatric trauma patients. Hospital Pediatrics2017;7(3):164.">Cutler 2017</a>). Moreover, the trauma itself generates an impairment of immunological defences of the patients, making them more prone to infections (<a href="./references#CD013864-bbs2-0108" title="PoriesSE , GamelliRL , MeadPB , GoodwinG , HarrisF , VacekP . The epidemiologic features of nosocomial infections in patients with trauma. Archives of Surgery1991;126(1):97-9.">Pories 1991</a>). </p> </section> <section id="CD013864-sec-0014"> <h4 class="title">Microbiology</h4> <p>The most common pathogens involved in hospital‐acquired pneumonia worldwide are <i>Enterobacteriaceae,</i> <i>Pseudomonas aeruginosa</i> , and <i>Staphylococcus aureus</i> (<a href="./references#CD013864-bbs2-0081" title="JonesRN . Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America2010;51(Suppl 1):81-7.">Jones 2010</a>; <a href="./references#CD013864-bbs2-0105" title="PatelJC , MollittDL , PieperP , TepasJJ . Nosocomial pneumonia in the pediatric trauma patient: a single center's experience. Critical Care Medicine2000;28(10):3530-3.">Patel 2000</a>; <a href="./references#CD013864-bbs2-0121" title="SrinivasanR , AsselinJ , GildengorinG , Wiener-KronishJ , FloriHR . A prospective study of ventilator-associated pneumonia in children. Pediatrics2009;123(4):1108-15.">Srinivasan 2009</a>; <a href="./references#CD013864-bbs2-0131" title="van derZwetWC , KaiserAM , vanElburgRM , BerkhofJ , FetterWP , ParlevlietGA , et al. Nosocomial infections in a Dutch neonatal intensive care unit: surveillance study with definitions for infection specifically adapted for neonates. Journal of Hospital Infection2005;61(4):300-11.">van der Zwet 2005</a>; <a href="./references#CD013864-bbs2-0135" title="Weiner-LastingerLM , AbnerS , BeninAL , EdwardsJR , KallenAJ , KarlssonM , et al. Antimicrobial-resistant pathogens associated with pediatric healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015-2017. Infection Control and Hospital Epidemiology2020;41(1):19-30. [PMID: 31762428]">Weiner‐Lastinger 2020</a>). Gram‐negative bacteria cause 67.5% of hospital‐acquired pneumonia in children, whereas gram‐positive bacteria and respiratory viruses cause 13% and 12.6% of hospital‐acquired pneumonia in children, respectively (<a href="./references#CD013864-bbs2-0134" title="WangP , DongL , ZhangL , XiaL . Etiology and epidemic characteristics of hospital acquired pneumonia in children. Zhonghua Er Ke za Zhi [Chinese Journal of Pediatrics]2010;48(6):465-8.">Wang 2010</a>). However, when comparing different geographical regions, the pathogens, their antibiotic susceptibility, the burden of disease, and diagnostic methods vary (<a href="./references#CD013864-bbs2-0040" title="BighamMT , AmatoR , BondurrantP , FridrikssonJ , KrawczeskiCD , RaakeJ , et al. Ventilator-associated pneumonia in the pediatric intensive care unit: characterizing the problem and implementing a sustainable solution. Journal of Pediatrics2009;154(4):582-7.">Bigham 2009</a>; <a href="./references#CD013864-bbs2-0077" title="IosifidisE , PitsavaG , RoilidesE . Ventilator-associated pneumonia in neonates and children: a systematic analysis of diagnostic methods and prevention. Future Microbiology2018;13:1431-46.">Iosifidis 2018</a>; <a href="./references#CD013864-bbs2-0131" title="van derZwetWC , KaiserAM , vanElburgRM , BerkhofJ , FetterWP , ParlevlietGA , et al. Nosocomial infections in a Dutch neonatal intensive care unit: surveillance study with definitions for infection specifically adapted for neonates. Journal of Hospital Infection2005;61(4):300-11.">van der Zwet 2005</a>). In particular, some studies show that viruses such as rhinovirus, influenza, and parainfluenza could be as common as bacterial pathogens in causing hospital‐acquired pneumonia in non‐ventilated children and adults (<a href="./references#CD013864-bbs2-0119" title="ShorrAF , ZilberbergMD , MicekST , KollefMH . Viruses are prevalent in non-ventilated hospital-acquired pneumonia. Respiratory Medicine2017;122:86-90.">Shorr 2017</a>; <a href="./references#CD013864-bbs2-0142" title="ZinnaSZ , LakshmananA , TanS , McClaughryR , ClarksonM , SooS , et al. Outcomes of nosocomial viral respiratory infections in high-risk neonates. Pediatrics2016;138(5):e20161675.">Zinna 2016</a>). Several observational studies show that infections caused by multidrug‐resistant (MDR) pathogens increase the risk of death, length of hospital stay, and healthcare costs (<a href="./references#CD013864-bbs2-0125" title="SuLH , ChenIL , TangYF , LeeJS , LiuJW . Increased financial burdens and lengths of stay in patients with healthcare-associated infections due to multidrug-resistant bacteria in intensive care units: a propensity-matched case-control study. PLOS ONE2020;15(5):e0233265.">Su 2020</a>). </p> <p>Furthermore, rhinovirus and enterovirus are the most commonly recognised pathogens causing hospital‐acquired viral respiratory infection in both adults and paediatric patients (<a href="./references#CD013864-bbs2-0046" title="ChowEJ , MermelLA . Hospital-acquired respiratory viral infections: incidence, morbidity, and mortality in pediatric and adult patients. Open Forum Infectious Diseases2017;4(1):ofx006.">Chow 2017</a>; <a href="./references#CD013864-bbs2-0142" title="ZinnaSZ , LakshmananA , TanS , McClaughryR , ClarksonM , SooS , et al. Outcomes of nosocomial viral respiratory infections in high-risk neonates. Pediatrics2016;138(5):e20161675.">Zinna 2016</a>).   </p> </section> <section id="CD013864-sec-0015"> <h4 class="title">Diagnosis</h4> <p>The diagnosis of hospital‐acquired pneumonia and ventilator‐associated pneumonia is based upon a combination of imaging test evidence of a lung disease plus clinical evidence that the infiltrate is of an infectious origin (<a href="./references#CD013864-bbs2-0083" title="KalilAC , MeterskyML , KlompasM , MuscedereJ , SweeneyDA , PalmerLB , et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America2016;63(5):61-111.">Kalil 2016</a>).  </p> <p> <ul id="CD013864-list-0001"> <li> <p>Radiological test (e.g. X‐ray image) could show a new and persistent or progressive and persistent lung infiltrate, consolidation, cavitation, or pneumatocele (in infants younger than one year old) (<a href="./references#CD013864-bbs2-0063" title="Gunalan A,  Sistla S,  Sastry AS,  VenkateswaranR . Concordance between the National Healthcare Safety Network (NHSN) Surveillance Criteria and Clinical Pulmonary Infection Score (CPIS) Criteria for Diagnosis of Ventilator-associated Pneumonia (VAP). Indian Journal of Critical Care Medicine2021;25(3):296-8.">Gunalan 2021</a>; <a href="./references#CD013864-bbs2-0094" title="MagillSS , KlompasM , BalkR , BurnsSM , DeutschmanCS , DiekemaD , et al. Developing a new, national approach to surveillance for ventilator-associated events. Critical Care Medicine2013;41(11):2467–75.">Magill 2013</a>). </p> </li> <li> <p>Sign and symptoms may vary depending on the age of the patient, as follows. </p> <ul id="CD013864-list-0002"> <li> <p><b>"For children &gt; 1 year old or ≤ 12 years old</b>: fever, leukocytosis, new onset of purulent sputum or change in character of sputum, increased respiratory secretions or increased suctioning requirements, new onset or worsening cough, dyspnoea, apnoea, or tachypnoea, rales or bronchial breath sounds, worsening gas exchange" (<a href="./references#CD013864-bbs2-0063" title="Gunalan A,  Sistla S,  Sastry AS,  VenkateswaranR . Concordance between the National Healthcare Safety Network (NHSN) Surveillance Criteria and Clinical Pulmonary Infection Score (CPIS) Criteria for Diagnosis of Ventilator-associated Pneumonia (VAP). Indian Journal of Critical Care Medicine2021;25(3):296-8.">Gunalan 2021</a>; <a href="./references#CD013864-bbs2-0094" title="MagillSS , KlompasM , BalkR , BurnsSM , DeutschmanCS , DiekemaD , et al. Developing a new, national approach to surveillance for ventilator-associated events. Critical Care Medicine2013;41(11):2467–75.">Magill 2013</a>). </p> </li> <li> <p><b>"For children &lt; 1 year old</b> worsening of gas exchange with increased oxygen requirements is the most common presentation, in association with temperature instability, leukopenia (≤ 4000 WBC/mm<sup>3</sup>) or leukocytosis (≥ 15,000 WBC/mm<sup>3</sup>), new onset of purulent sputum or change in character of sputum, increased respiratory secretions or increased suctioning requirements, apnoea, tachypnoea, nasal flaring, wheezing, cough, bradycardia (&lt; 100 beats/min) or tachycardia (&gt; 170 beats/min)" (<a href="./references#CD013864-bbs2-0063" title="Gunalan A,  Sistla S,  Sastry AS,  VenkateswaranR . Concordance between the National Healthcare Safety Network (NHSN) Surveillance Criteria and Clinical Pulmonary Infection Score (CPIS) Criteria for Diagnosis of Ventilator-associated Pneumonia (VAP). Indian Journal of Critical Care Medicine2021;25(3):296-8.">Gunalan 2021</a>; <a href="./references#CD013864-bbs2-0094" title="MagillSS , KlompasM , BalkR , BurnsSM , DeutschmanCS , DiekemaD , et al. Developing a new, national approach to surveillance for ventilator-associated events. Critical Care Medicine2013;41(11):2467–75.">Magill 2013</a>). </p> </li> </ul> </li> </ul> </p> <p>The clinical symptoms of hospital‐acquired pneumonia are non‐specific, and no combination of signs and symptoms has been found to be highly sensitive or specific for the diagnosis (<a href="./references#CD013864-bbs2-0056" title="FabregasN , EwigS , TorresA , El-EbiaryM , RamirezJ , deLa BellacasaJP , et al. Clinical diagnosis of ventilator associated pneumonia revisited: comparative validation using immediate post-mortem lung biopsies. Thorax1999;54(10):867-73. [PMID: 10491448]">Fabregas 1999</a>; <a href="./references#CD013864-bbs2-0058" title="FerrerM , SequeiraT , CillonizC , DominedoC , BassiGL , Martin-LoechesI , et al. Ventilator-associated pneumonia and PaO2/FIO2 diagnostic accuracy: changing the paradigm?Journal of Clinical Medicine2019;8(8):1-13.">Ferrer 2019</a>). Nevertheless, no gold standard exists for the diagnosis of hospital‐acquired pneumonia (<a href="./references#CD013864-bbs2-0045" title="ChangI , SchiblerA . Ventilator associated pneumonia in children. Paediatric Respiratory Reviews2016;20:10-6.">Chang 2016</a>; <a href="./references#CD013864-bbs2-0077" title="IosifidisE , PitsavaG , RoilidesE . Ventilator-associated pneumonia in neonates and children: a systematic analysis of diagnostic methods and prevention. Future Microbiology2018;13:1431-46.">Iosifidis 2018</a>). </p> </section> </section> <section id="CD013864-sec-0016"> <h3 class="title" id="CD013864-sec-0016">Description of the intervention</h3> <p>The treatment of hospital‐acquired pneumonia can be either empirical (initiation of an antibiotic regimen before the aetiological pathogen is known) or based on the results of microbiologic studies. The decision to treat empirically is based primarily on the clinical presentation of the patient (<a href="./references#CD013864-bbs2-0083" title="KalilAC , MeterskyML , KlompasM , MuscedereJ , SweeneyDA , PalmerLB , et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America2016;63(5):61-111.">Kalil 2016</a>; <a href="./references#CD013864-bbs2-0129" title="TorresA , NiedermanMS , ChastreJ , EwigS , Fernandez-VandellosP , HanbergerH , et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). European Respiratory Journal2017;50(3):1-26.">Torres 2017</a>). Early initiation and appropriate antimicrobial therapy of hospital‐acquired pneumonia has been shown to significantly reduce morbidity and mortality in adults (<a href="./references#CD013864-bbs2-0085" title="KellyDN , Martin-LoechesI . Comparing current US and European guidelines for nosocomial pneumonia. Current Opinion in Pulmonary Medicine2019;25(3):263-70.">Kelly 2019</a>). Current guidelines for adults recommend that the choice of antibiotics should be based on local antibiograms, local distribution of pathogens, and individual risk factors for serious infection, MDR pathogens, or if <i>P aeruginosa</i> is suspected (<a href="./references#CD013864-bbs2-0083" title="KalilAC , MeterskyML , KlompasM , MuscedereJ , SweeneyDA , PalmerLB , et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America2016;63(5):61-111.">Kalil 2016</a>; <a href="./references#CD013864-bbs2-0085" title="KellyDN , Martin-LoechesI . Comparing current US and European guidelines for nosocomial pneumonia. Current Opinion in Pulmonary Medicine2019;25(3):263-70.">Kelly 2019</a>; <a href="./references#CD013864-bbs2-0129" title="TorresA , NiedermanMS , ChastreJ , EwigS , Fernandez-VandellosP , HanbergerH , et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). European Respiratory Journal2017;50(3):1-26.">Torres 2017</a>). </p> <p>Patients assessed as being at low risk of antibiotic resistance and early‐onset hospital‐acquired pneumonia or ventilator‐associated pneumonia are recommended for initial empiric therapy with a narrow‐spectrum antibiotic, whereas high‐risk patients will require broader therapy with a combination of different classes of antimicrobials (<a href="./references#CD013864-bbs2-0085" title="KellyDN , Martin-LoechesI . Comparing current US and European guidelines for nosocomial pneumonia. Current Opinion in Pulmonary Medicine2019;25(3):263-70.">Kelly 2019</a>; <a href="./references#CD013864-bbs2-0102" title="National Institute for Health and Care Excellence. Pneumonia (hospital-acquired): antimicrobial prescribing guideline. www.nice.org.uk/guidance/ng139 (accessed prior to 21 October 2021).">NICE 2019</a>; <a href="./references#CD013864-bbs2-0129" title="TorresA , NiedermanMS , ChastreJ , EwigS , Fernandez-VandellosP , HanbergerH , et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). European Respiratory Journal2017;50(3):1-26.">Torres 2017</a>). </p> <p>In the case of low risk of methicillin‐resistant <i>S aureus</i> (MRSA), the American Thoracic Society guidelines recommend piperacillin‐tazobactam, cefepime, levofloxacin, imipenem, or meropenem for <i>S aureus</i> , <i>P aeruginosa</i>, and other gram‐negative bacilli (the last only for patients suspected of having ventilator‐associated pneumonia) (<a href="./references#CD013864-bbs2-0083" title="KalilAC , MeterskyML , KlompasM , MuscedereJ , SweeneyDA , PalmerLB , et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America2016;63(5):61-111.">Kalil 2016</a>). </p> <p>If there is a risk of MRSA, the American Thoracic Society guidelines recommend vancomycin or linezolid (<a href="./references#CD013864-bbs2-0083" title="KalilAC , MeterskyML , KlompasM , MuscedereJ , SweeneyDA , PalmerLB , et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America2016;63(5):61-111.">Kalil 2016</a>). Whether to initiate monotherapy or combination therapy depends on the risk of gram‐negative bacteria or risk of antimicrobial resistance, or both (<a href="./references#CD013864-bbs2-0083" title="KalilAC , MeterskyML , KlompasM , MuscedereJ , SweeneyDA , PalmerLB , et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America2016;63(5):61-111.">Kalil 2016</a>; <a href="./references#CD013864-bbs2-0136" title="WeissSL , PetersMJ , AlhazzaniW , AgusMSD , FloriHR , InwaldDP , et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Pediatric Critical Care Medicine2020;21(2):e52-106. [PMID: 32032273]">Weiss 2020</a>). </p> <p>Antibiotics such as aminoglycoside and colistin are not recommended, unless alternative agents with adequate gram‐negative activity are unavailable (<a href="./references#CD013864-bbs2-0083" title="KalilAC , MeterskyML , KlompasM , MuscedereJ , SweeneyDA , PalmerLB , et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America2016;63(5):61-111.">Kalil 2016</a>). </p> <p>The role of viruses in causing hospital‐acquired pneumonia in neonates and children might also be taken into account. The confirmation of a viral organism when routine cultures are negative might facilitate antibiotic discontinuation (<a href="./references#CD013864-bbs2-0119" title="ShorrAF , ZilberbergMD , MicekST , KollefMH . Viruses are prevalent in non-ventilated hospital-acquired pneumonia. Respiratory Medicine2017;122:86-90.">Shorr 2017</a>). </p> <p>Guidelines for the treatment of hospital‐acquired pneumonia focus primarily on adults (<a href="./references#CD013864-bbs2-0083" title="KalilAC , MeterskyML , KlompasM , MuscedereJ , SweeneyDA , PalmerLB , et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America2016;63(5):61-111.">Kalil 2016</a>; <a href="./references#CD013864-bbs2-0085" title="KellyDN , Martin-LoechesI . Comparing current US and European guidelines for nosocomial pneumonia. Current Opinion in Pulmonary Medicine2019;25(3):263-70.">Kelly 2019</a>; <a href="./references#CD013864-bbs2-0102" title="National Institute for Health and Care Excellence. Pneumonia (hospital-acquired): antimicrobial prescribing guideline. www.nice.org.uk/guidance/ng139 (accessed prior to 21 October 2021).">NICE 2019</a>; <a href="./references#CD013864-bbs2-0129" title="TorresA , NiedermanMS , ChastreJ , EwigS , Fernandez-VandellosP , HanbergerH , et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). European Respiratory Journal2017;50(3):1-26.">Torres 2017</a>); however, it should be noted that children differ from adults with hospital‐acquired pneumonia due to differences in pathogenesis, pharmacokinetics, and types of pathogens (<a href="./references#CD013864-bbs2-0057" title="FernandezE , PerezR , HernandezAH , PilarT , ArtetaMA , RamosJT . Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics2011;3(1):53-72.">Fernandez 2011</a>; <a href="./references#CD013864-bbs2-0078" title="JainS , WilliamsDJ , ArnoldSR , AmpofoK , BramleyAM , ReedC , et al. Community-acquired pneumonia requiring hospitalization among U.S. children. New England Medical Journal2015;372(9):835-45.">Jain 2015</a>; <a href="./references#CD013864-bbs2-0124" title="StephensonT . How children's responses to drugs differ from adults. British Journal of Clinical Pharmacology2005;59(6):670-3.">Stephenson 2005</a>). Consequently, evidence from adult studies cannot be directly transmitted to treatment regimens in children. </p> </section> <section id="CD013864-sec-0017"> <h3 class="title" id="CD013864-sec-0017">How the intervention might work</h3> <p>Hospital‐acquired pneumonia could be both a viral or bacterial infection. Considering that viral pneumonia does not require antibiotic therapy unless a mixed infection or secondary bacterial infection is suspected, one of the main objectives of empirical treatment of hospital‐acquired pneumonia is to kill the bacteria. Antibiotics are therefore an essential part of the treatment of hospital‐acquired pneumonia. </p> <p>Antibiotics may be classified by their: "1) mechanism of action (bactericidal or bacteriostatic); 2) bacterial spectrum (broad or narrow); and 3) chemical structure (e.g. penicillins, aminoglycosides, macrolides, glycopeptides, or quinolones)" (<a href="./references#CD013864-bbs2-0039" title="BérdyJ . Bioactive microbial metabolites. Journal of Antibiotics2005;58(1):1-26.">Bérdy 2005</a>; <a href="./references#CD013864-bbs2-0088" title="KorangSK , SafiS , NavaC , GuptaM , GordonA , GreisenG , et al. Antibiotic regimens for early-onset neonatal sepsis. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD013837. [DOI: 10.1002/14651858.CD013837.pub2]">Korang 2021b</a>; <a href="./references#CD013864-bbs2-0089" title="KorangSK , SafiS , NavaC , GreisenG , GuptaM , Lausten-ThomsenU , et al. Antibiotic regimens for late-onset neonatal sepsis. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD013836. [DOI: 10.1002/14651858.CD013836.pub2]">Korang 2021c</a>). </p> <p>The empirical treatment for suspected hospital‐acquired pneumonia should provide coverage for the most likely bacteria. This may result in antibiotic combination therapy if there is a suspicion of either MDR pathogens or severe infection (<a href="./references#CD013864-bbs2-0083" title="KalilAC , MeterskyML , KlompasM , MuscedereJ , SweeneyDA , PalmerLB , et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America2016;63(5):61-111.">Kalil 2016</a>; <a href="./references#CD013864-bbs2-0136" title="WeissSL , PetersMJ , AlhazzaniW , AgusMSD , FloriHR , InwaldDP , et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Pediatric Critical Care Medicine2020;21(2):e52-106. [PMID: 32032273]">Weiss 2020</a>). The rationale of combination therapy is to widen the spectrum of the empirical antibiotic regimen to increase the likelihood of covering the causative bacteria. Theoretically, combination therapy might also suppress the occurrence of resistant subpopulations (<a href="./references#CD013864-bbs2-0035" title="AllanJD , MoelleringRC . Management of infections caused by gram-negative bacilli: the role of antimicrobial combinations. Review of Infectious Diseases1985;7(Suppl 4):559-71.">Allan 1985</a>; <a href="./references#CD013864-bbs2-0097" title="MilatovicD , BravenyI . Development of resistance during antibiotic therapy. European Journal of Clinical Microbiology1987;6(3):234-44.">Milatovic 1987</a>). A recent guideline has been created to determine whether to continue or stop the empirical antibiotic after 48 to 72 hours of treatment (<a href="./references#CD013864-bbs2-0117" title="SheinSL , KaramO , BeardsleyA , KarsiesT , PrenticeE , TarquinioKM , et al. Development of an antibiotic guideline for children with suspected ventilator-associated infections. Pediatric Critical Care Medicine2019;20(8):697-706.">Shein 2019</a>) </p> <p>An optimal empirical antibiotic treatment would ideally reduce disease progression of the pneumonia and avoid the development of sepsis and septic shock (<a href="./references#CD013864-bbs2-0045" title="ChangI , SchiblerA . Ventilator associated pneumonia in children. Paediatric Respiratory Reviews2016;20:10-6.">Chang 2016</a>; <a href="./references#CD013864-bbs2-0136" title="WeissSL , PetersMJ , AlhazzaniW , AgusMSD , FloriHR , InwaldDP , et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Pediatric Critical Care Medicine2020;21(2):e52-106. [PMID: 32032273]">Weiss 2020</a>). This would in turn reduce the risk of death and complications (<a href="./references#CD013864-bbs2-0045" title="ChangI , SchiblerA . Ventilator associated pneumonia in children. Paediatric Respiratory Reviews2016;20:10-6.">Chang 2016</a>). By clearing the pathogen, an optimal antibiotic regimen would also speed up the recovery and thereby reduce the discomfort and work of breathing that a child may experience during such an infection. </p> </section> <section id="CD013864-sec-0018"> <h3 class="title" id="CD013864-sec-0018">Why it is important to do this review</h3> <p>Hospital‐acquired pneumonia is one of the most common nosocomial infections amongst neonates and children (<a href="./references#CD013864-bbs2-0044" title="CernadaM , AguarM , BrugadaM , GutiérrezA , LópezJL , CastellM , et al. Ventilator-associated pneumonia in newborn infants diagnosed with an invasive bronchoalveolar lavage technique: a prospective observational study. Pediatric Critical Care Medicine2013;14(1):55-61.">Cernada 2013</a>; <a href="./references#CD013864-bbs2-0107" title="PolinRA , DensonS , BradyMT , Committee on Fetus and Newborn, Committee on Infectious Diseases. Epidemiology and diagnosis of health care-associated infections in the NICU. Pediatrics2012;129(4):e1104-9.">Polin 2012</a>). Current guidelines are directed solely towards adults (<a href="./references#CD013864-bbs2-0085" title="KellyDN , Martin-LoechesI . Comparing current US and European guidelines for nosocomial pneumonia. Current Opinion in Pulmonary Medicine2019;25(3):263-70.">Kelly 2019</a>; <a href="./references#CD013864-bbs2-0095" title="Martin-LoechesI , RodriguezAH , TorresA . New guidelines for hospital-acquired pneumonia/ventilator-associated pneumonia: USA vs. Europe. Current Opinion in Critical Care2018;24(5):347-52.">Martin‐Loeches 2018</a>). Most of our understanding of hospital‐acquired pneumonia in children is derived from adult studies; however, there exist many differences between neonates/children and adults with respect to hospital‐acquired pneumonia (such as the pattern of causative agents isolated, risk factors, and diagnostic methods) (<a href="./references#CD013864-bbs2-0077" title="IosifidisE , PitsavaG , RoilidesE . Ventilator-associated pneumonia in neonates and children: a systematic analysis of diagnostic methods and prevention. Future Microbiology2018;13:1431-46.">Iosifidis 2018</a>; <a href="./references#CD013864-bbs2-0133" title="VijayG , MandalA , SankarJ , KapilA , LodhaR , KabraSK . Ventilator associated pneumonia in pediatric intensive care unit: incidence, risk factors and etiological agents. Indian Journal of Pediatrics2018;85(10):861-6.">Vijay 2018</a>). The certainty of evidence from adult studies will also generally tend to be downgraded due to the indirectness of the evidence (<a href="./references#CD013864-bbs2-0065" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 8. Rating the quality of evidence - indirectness. Journal of Clinical Epidemiology2011;64(12):1303-10.">Guyatt 2011a</a>; <a href="./references#CD013864-bbs2-0136" title="WeissSL , PetersMJ , AlhazzaniW , AgusMSD , FloriHR , InwaldDP , et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Pediatric Critical Care Medicine2020;21(2):e52-106. [PMID: 32032273]">Weiss 2020</a>). No previous systematic review with meta‐analysis has assessed the benefits and harms of different antibiotic regimens for children with hospital‐acquired pneumonia. There is a need for a systematic review with meta‐analysis to provide the necessary evidence for the effects of antibiotics in children with hospital‐acquired pneumonia. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013864-sec-0019" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013864-sec-0019"></div> <p>To assess the beneficial and harmful effects of different antibiotic regimens for hospital‐acquired pneumonia in neonates and children. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013864-sec-0020" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013864-sec-0020"></div> <section id="CD013864-sec-0021"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013864-sec-0022"> <h4 class="title">Types of studies</h4> <p>We included randomised clinical trials reported as full text, abstract only, and unpublished data. We excluded trials with a cross‐over design and cluster‐randomised trials. </p> </section> <section id="CD013864-sec-0023"> <h4 class="title">Types of participants</h4> <p>We included neonates (&lt; 28 days old) and children (&lt; 18 years of age) suspected of, or diagnosed with, hospital‐acquired pneumonia (as defined by the trialists). </p> </section> <section id="CD013864-sec-0024"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing one antibiotic regimen with any other antibiotic regimen or placebo. We included the following antibiotic groups. </p> <p> <ol id="CD013864-list-0003"> <li> <p>Beta‐lactam antibiotics</p> <ol id="CD013864-list-0004"> <li> <p>Narrow‐spectrum penicillins (penicillin G, oxacillin, dicloxacillin, cloxacillin, nafcillin, and methicillin). </p> </li> <li> <p>Broad‐spectrum penicillins (e.g. amoxicillin, ampicillin, piperacillin, ticarcillin, mezlocillin, and carbenicillin). </p> </li> <li> <p>Penicillins combined with beta‐lactamase inhibitors (e.g. piperacillin/tazobactam and amoxicillin/clavulanic acid). </p> </li> <li> <p>Cephalosporins (e.g. cefuroxime, cefotaxime, ceftazidime, cefazolin, cefalexin, cefotetan, cefoxitin, ceftriaxone, cefepime, cefazolin, ceftobiprole, and cefoperazone). </p> </li> <li> <p>Carbapenems (e.g. meropenem, imipenem, doripenem, and ertapenem).</p> </li> <li> <p>Monobactams (aztreonam).</p> </li> </ol> </li> <li> <p>Aminoglycosides (e.g. amikacin, tobramycin, and gentamicin).</p> </li> <li> <p>Quinolones (e.g. ciprofloxacin, ofloxacin, temafloxacin, garenoxacin, gatifloxacin, grepafloxacin, sparfloxacin, levofloxacin, and moxifloxacin). </p> </li> <li> <p>Macrolides (e.g. azithromycin, clarithromycin, and erythromycin).</p> </li> <li> <p>Glycopeptides (e.g. vancomycin and teicoplanin).</p> </li> <li> <p>Lincosamides (e.g. clindamycin).</p> </li> <li> <p>Antibacerial oxazolidinone agents (e.g. linezolid).</p> </li> <li> <p>Nitroimidazoles (e.g. metronidazole) (<a href="./references#CD013864-bbs2-0086" title="KorangSK , SafiS , GluudC , Lausten-ThomsenU , JakobsenJC . Antibiotic regimens for neonatal sepsis - a protocol for a systematic review with meta-analysis. Systematic Reviews2019;8(1):306.">Korang 2019</a>). </p> </li> </ol> </p> <p>We also planned to assess any antibiotic regimen (such as either piperacillin‐tazobactam, cefepime, levofloxacin, or meropenem/imipenem) that covers patients at low risk of having an MDR pathogen compared to an antibiotic regimen (such as a combination of either piperacillin‐tazobactam, cefepime/ceftazidime, levofloxacin/ciprofloxacin, meropenem/imipenem, or amikacin/gentamicin/tobramycin plus either vancomycin or linezolid) that covers patients at high risk of having an MDR pathogen. </p> </section> <section id="CD013864-sec-0025"> <h4 class="title">Types of outcome measures</h4> <section id="CD013864-sec-0026"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD013864-list-0005"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Proportion of participants with one or more serious adverse events. We used the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ‐ Good Clinical Practice (ICH‐GCP) definition of a serious adverse event, which is any untoward medical occurrence that resulted in death, was life‐threatening, required hospitalisation or prolonging of existing hospitalisation, and resulted in persistent or significant disability or jeopardised the participant (<a href="./references#CD013864-bbs2-0076" title="International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Good Clinical Practice (GCP) Guideline Integrated Addendum E6(R2); November 2016. ich.org/page/efficacy-guidelines (accessed prior to 21 October 2021).">ICH‐GCP 2016</a>). If the trialists did not use the ICH‐GCP definition, we included the data if the trialists used the term 'serious adverse event'. If the trialists did not use the ICH‐GCP definition or this term, then we included the data if the event clearly fulfilled the ICH‐GCP definition for a serious adverse event. We planned to assess each type of serious adverse event separately (<a href="./references#CD013864-bbs2-0088" title="KorangSK , SafiS , NavaC , GuptaM , GordonA , GreisenG , et al. Antibiotic regimens for early-onset neonatal sepsis. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD013837. [DOI: 10.1002/14651858.CD013837.pub2]">Korang 2021b</a>; <a href="./references#CD013864-bbs2-0089" title="KorangSK , SafiS , NavaC , GreisenG , GuptaM , Lausten-ThomsenU , et al. Antibiotic regimens for late-onset neonatal sepsis. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD013836. [DOI: 10.1002/14651858.CD013836.pub2]">Korang 2021c</a>). </p> </li> </ol> </p> </section> <section id="CD013864-sec-0027"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013864-list-0006"> <li> <p>Health‐related quality of life (any continuous scale used by the trialists).</p> </li> <li> <p>Pneumonia‐related mortality (as defined by trialists).</p> </li> <li> <p>Proportion of participants with one or more non‐serious adverse event (any adverse event which was not classified as "serious" or which did not clearly fulfilled the ICH‐GCP definition for a serious adverse event ). We planned to assess each reported adverse event separately. </p> </li> <li> <p>Proportion of participants with treatment failure. We defined treatment failure as clinical deterioration or recurrence of clinical signs leading to any modification of the assigned empirical antibiotic treatment (we accepted similar definitions as defined by the trialists). </p> </li> </ol> </p> <p>We used the trial results reported closest to one month as our primary time point of interest for all outcomes. </p> </section> </section> </section> <section id="CD013864-sec-0028"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013864-sec-0029"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases from inception to present.</p> <p> <ol id="CD013864-list-0007"> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (1 February 2021, Issue 2). </p> </li> <li> <p>MEDLINE Ovid (from 1946 to 1 February 2021).</p> </li> <li> <p>Embase Ovid (from 1974 to 1 February 2021).</p> </li> </ol> </p> <p>We also searched the following databases.</p> <p> <ol id="CD013864-list-0008"> <li> <p>CINAHL via EBSCOhost (Cumulative Index to Nursing and Allied Health Literature) (from 1961 to 1 February 2021). </p> </li> <li> <p>PsycINFO via EBSCOhost (from 1967 to 1 February 2021).</p> </li> <li> <p>Science Citation Index Expanded (Web of Science) (from 1900 to 1 February 2021) and Conference Proceedings Citation Index – Science (Web of Science) (from 1990 to 1 February 2021). </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database) (from 1982 to 1 February 2021). </p> </li> </ol> </p> <p>We used the search strategy described in <a href="./appendices#CD013864-sec-0099">Appendix 1</a> to search MEDLINE. We combined the MEDLINE search with the Cochrane Highly Sensitive Search Strategy for randomised trials: sensitivity and precision‐maximising version (2008 revision) (<a href="./references#CD013864-bbs2-0091" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Lefebvre 2011</a>). </p> <p>We also conducted a search of the US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.ClinicalTrials.gov" target="_blank">www.clinicaltrials.gov</a>) (1 February 2021) and the World Health Organization International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) (1 February 2021). </p> </section> <section id="CD013864-sec-0030"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all primary studies and review articles for additional references. We contacted experts in the field to identify additional unpublished materials. </p> <p>In an effort to identify unpublished trials, we searched clinical trial registers of Europe and the USA and the websites of pharmaceutical companies, the US Food and Drug Administration (FDA), and the European Medicines Agency (EMA). </p> <p>We searched for errata or retractions from the included studies published in full text on PubMed (23 March 2021) (<a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>). </p> </section> </section> <section id="CD013864-sec-0031"> <h3 class="title" id="CD013864-sec-0031">Data collection and analysis</h3> <section id="CD013864-sec-0032"> <h4 class="title">Selection of studies</h4> <p>Three review authors (SKK, CN, SPM) independently screened the titles and abstracts of records identified by the search for potential inclusion in the review. We retrieved selected full‐text study reports/publications, and three review authors (SKK, CN, SPM) independently screened the full‐texts and identified trials for inclusion, and identified and recorded reasons for exclusion of the ineligible studies. Any disagreements were resolved through discussion or by consulting a fourth review author (JCJ) if required. We excluded duplicates and collated multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="#CD013864-fig-0001">Figure 1</a>) and <a href="./references#CD013864-sec-0120" title="">Characteristics of excluded studies</a> table (<a href="./references#CD013864-bbs2-0099" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. BMJ2009;339:2535.">Moher 2009</a>). We did not impose any language or publication restrictions. </p> <div class="figure" id="CD013864-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD013864-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_n/nCD013864-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD013864-sec-0033"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form to record study characteristics and outcome data that we piloted on at least one study in the review. One review author (SKK or CN or SPM) extracted trial characteristics from the included trials. We extracted the following trial characteristics. </p> <p> <ol id="CD013864-list-0009"> <li> <p>Methods: trial design, total duration of trial, number of trial centres and location, trial setting, withdrawals, and date of trial. </p> </li> <li> <p>Participants: number of participants, mean age, age range, sex, microbial agent isolated, severity of condition, diagnostic criteria, baseline lung function, smoking history (of participants or parents, or both), inclusion criteria, and exclusion criteria. </p> </li> <li> <p>Interventions: intervention (including dosage, route of administration, and length of empirical treatment), comparison, co‐interventions, and excluded medications. </p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for trial, and notable conflicts of interest of trial authors.</p> </li> </ol> </p> <p>Three review authors (SKK, CN, SPM) independently extracted outcome data from the included trials. We noted in the <a href="./references#CD013864-sec-0119" title="">Characteristics of included studies</a> table if outcome data were not reported in a useable way. Any disagreements were resolved by consensus or by consulting a fourth review author (JCJ). One review author (SKK) entered the data into Review Manager 5 software (<a href="./references#CD013864-bbs2-0110" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We double‐checked that data were entered correctly by comparing the data presented in the systematic review with the study reports. </p> </section> <section id="CD013864-sec-0034"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (SKK, CN, SPM) independently assessed the risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013864-bbs2-0071" title="HigginsJP , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). Any disagreements were resolved by discussion or by involving another review author (JCJ). We assessed risk of bias according to the following domains. </p> <p> <ol id="CD013864-list-0010"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ol> </p> <p>We graded each potential source of bias as low, high, or unclear and provided a quote from the study report together with a justification for our judgement in the risk of bias table. We summarised the risk of bias judgements across different studies for each of the domains listed. We considered the domains blinding of outcome assessment, incomplete outcome data, and selective outcome reporting separately for different key outcomes, where necessary. Where information on risk of bias related to unpublished data or correspondence with a trialist, we noted this in the risk of bias table. </p> <p>When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. </p> <section id="CD013864-sec-0035"> <h5 class="title">Overall risk of bias</h5> <p>We assessed overall risk of bias as follows.</p> <p> <ol id="CD013864-list-0011"> <li> <p>Low risk of bias: we classified the outcome of a trial as overall 'low risk of bias' only if all domains were classified as at low risk of bias. </p> </li> <li> <p>Unclear risk of bias: we classified the outcome of a trial as overall 'unclear' risk of bias if one or more domains were classified as unclear, and no domain was at high risk of bias. </p> </li> <li> <p>High risk of bias: we classified the outcome of a trial as overall 'high risk of bias' if at least one domain was classified as high risk of bias. </p> </li> </ol> </p> <p>See <a href="./appendices#CD013864-sec-0100">Appendix 2</a> for further details. </p> <p>We planned to assess confidence in network meta‐analysis results using CINeMA (Confidence in Network Meta‐Analysis) (<a href="./references#CD013864-bbs2-0103" title="NikolakopoulouA , HigginsJP , PapakonstantinouT , ChaimaniA , Del GiovaneC , EggerM , et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLOS Medicine2020;17(4):e1003082.">Nikolakopoulou 2020</a>; <a href="./references#CD013864-bbs2-0104" title="PapakonstantinouT , NikolakopoulouA , HigginsJP , EggerM , SalantiG . CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis. Campbell Systematic Reviews - Wiley Online Library2020;16(1):e1080.">Papakonstantinou 2020</a>). </p> </section> <section id="CD013864-sec-0036"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to the published protocol (<a href="./references#CD013864-bbs2-0143" title="KorangSK , NavaC , NygaardU , JakobsenJC . Antibiotics for hospital-acquired pneumonia in neonates and children. Cochrane Database of Systematic Reviews2021, Issue 1. Art. No: CD013864. [DOI: 10.1002/14651858.CD013864]">Korang 2021a</a>), and reported any deviations from it in the <a href="#CD013864-sec-0117">Differences between protocol and review</a> section. </p> </section> </section> <section id="CD013864-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <p>We entered the outcome data for each trial into the data tables in Review Manager 5 to calculate the treatment effects (<a href="./references#CD013864-bbs2-0110" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> <section id="CD013864-sec-0038"> <h5 class="title">Dichotomous outcomes</h5> <p>We calculated risk ratios (RRs) with 95% confidence interval (CI) for dichotomous outcomes. </p> </section> <section id="CD013864-sec-0039"> <h5 class="title">Continuous outcomes</h5> <p>We planned to calculate the mean differences (MDs) and the standardised mean difference (SMD) with 95% CI for continuous outcomes. </p> <p>We planned to perform meta‐analysis only if the treatments, participants, and the underlying clinical question were similar enough for pooling to make sense. </p> </section> </section> <section id="CD013864-sec-0040"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the participating children in individually randomised trials.</p> </section> <section id="CD013864-sec-0041"> <h4 class="title">Dealing with missing data</h4> <p>We contacted trial investigators to obtain missing outcome data where possible. If the missing data were unobtainable, we explored the impact of the missing data in a sensitivity analysis (<a href="#CD013864-sec-0047">Sensitivity analysis</a>). </p> <p>If numerical outcome data such as standard deviations or correlation coefficients were missing, and they could not be obtained from the trial authors, we would calculate them from other available statistics such as P values according to the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013864-bbs2-0072" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). </p> <p>We did not impute missing values for any outcomes in our primary analysis. We planned to impute data in two sensitivity analyses. </p> </section> <section id="CD013864-sec-0042"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to visually inspect forest plots for signs of heterogeneity, and to explore possible heterogeneity in our prespecified subgroup analyses. We inspected trial characteristics across trials to identify clinical heterogeneity. We planned to assess the presence of statistical heterogeneity by the Chi<sup>2</sup> test (threshold P &lt; 0.10) and to measure the quantities of heterogeneity using the I<sup>2</sup> statistic (<a href="./references#CD013864-bbs2-0068" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21(11):1539-58. [DOI: 10.1002/sim.1186] [PMID: 12111919]">Higgins 2002</a>; <a href="./references#CD013864-bbs2-0069" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ (Clinical Research Ed.)2003;327(7414):557-60.">Higgins 2003</a>). If we detected moderate or high heterogeneity, we explored possible causes (e.g. differences in study design, participants, interventions, or completeness of outcome assessments) (<a href="./references#CD013864-bbs2-0086" title="KorangSK , SafiS , GluudC , Lausten-ThomsenU , JakobsenJC . Antibiotic regimens for neonatal sepsis - a protocol for a systematic review with meta-analysis. Systematic Reviews2019;8(1):306.">Korang 2019</a>). </p> <p>We defined the level of heterogeneity as:</p> <p> <ol id="CD013864-list-0012"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity; and</p> </li> <li> <p>75% to 100%: may represent considerable heterogeneity.</p> </li> </ol> </p> <p>We would evaluate whether a meta‐analysis should be avoided if the level of heterogeneity indicated that pooling of data was not justified (<a href="./references#CD013864-bbs2-0072" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). </p> </section> <section id="CD013864-sec-0043"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to use a funnel plot to assess publication bias only if we included 10 or more trials. We planned to visually inspect funnel plots to assess risk of bias. We planned to test asymmetry with the Harbord test (<a href="https://archie.cochrane.org/sections/documents/view?version=z1901251313435217790711424296060&amp;format=REVMAN#REF-Harbord-2006" target="_blank">Harbord 2006</a>). </p> </section> <section id="CD013864-sec-0044"> <h4 class="title">Data synthesis</h4> <p>We planned to pool data from trials that we judged to be clinically homogeneous. We planned to perform meta‐analysis only if more than one trial provided relevant data in any single comparison. </p> <section id="CD013864-sec-0045"> <h5 class="title">Meta‐analysis</h5> <p>We planned to undertake meta‐analyses according to the recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, <a href="./references#CD013864-bbs2-0072" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>, and our protocol (<a href="./references#CD013864-bbs2-0143" title="KorangSK , NavaC , NygaardU , JakobsenJC . Antibiotics for hospital-acquired pneumonia in neonates and children. Cochrane Database of Systematic Reviews2021, Issue 1. Art. No: CD013864. [DOI: 10.1002/14651858.CD013864]">Korang 2021a</a>). We used Review Manager 5 software (<a href="./references#CD013864-bbs2-0110" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> <p>We planned to assess our intervention effects with both fixed‐effect and random‐effects meta‐analyses (<a href="./references#CD013864-bbs2-0050" title="DeMetsDL . Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine1987;6(3):341-50.">DeMets 1987</a>; <a href="./references#CD013864-bbs2-0052" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7(3):177-88.">DerSimonian 1986</a>). We planned to use the more conservative point estimate of the two. We considered the point estimate closest to zero effect as the more conservative point (<a href="./references#CD013864-bbs2-0079" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). As we have chosen two primary outcomes, we considered a P value of 0.033 or less as the threshold for evidence of a difference (<a href="./references#CD013864-bbs2-0079" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). We planned to use the eight‐step procedure provided by Jakobsen and colleagues to assess if the threshold for any evidence of a difference was crossed (<a href="./references#CD013864-bbs2-0079" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). Where data were available from only one trial, we planned to use Fisher’s exact test for dichotomous data (<a href="./references#CD013864-bbs2-0059" title="FisherRA . On the interpretation of χ2 from contingency tables, and the calculation of P. Journal of the Royal Statistical Society1922;85(1):87-94.">Fisher 1922</a>). </p> <p>We planned that if the ranking of the identified interventions was unclear based on aggregating the meta‐analysis results, we would perform a network meta‐analysis (see <a href="./appendices#CD013864-sec-0109">Appendix 3</a>). </p> <p>In addition to the primary meta‐analysis, we planned to use Trial Sequential Analysis (TSA) as a secondary analysis (see <a href="./appendices#CD013864-sec-0110">Appendix 4</a>). </p> </section> </section> <section id="CD013864-sec-0046"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses.</p> <p> <ol id="CD013864-list-0013"> <li> <p>Trials at high risk of bias compared to trials at low risk of bias.</p> </li> <li> <p>Age: newborn (less than 1 month), infants (1 month to 1 year), children of preschool age (1 to 5 years), children of school age (5 to 12 years), adolescents (older than 12 years). </p> </li> <li> <p>Trials from high‐income countries compared to trials from low‐ and middle‐income countries, as defined by the World Bank (<a href="./references#CD013864-bbs2-0140" title="World Bank. World Bank country and lending groups. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed 14 May 2020).">World Bank 2020</a>). </p> </li> <li> <p>Suspected hospital‐acquired pneumonia without radiological verification or culture of respiratory specimens compared to hospital‐acquired pneumonia with radiological verification or culture of respiratory specimens at randomisation. </p> </li> <li> <p>Empirical compared to targeted treatment based on bacterial cultures, if possible.</p> </li> <li> <p>Hospital‐acquired pneumonia compared to ventilator‐associated pneumonia.</p> </li> <li> <p>Early‐onset compared to late‐onset, defined as onset of ventilator‐associated pneumonia before or after four days. </p> </li> <li> <p>Length of antibiotic treatment: three days or shorter, four to seven days, or longer than seven days. </p> </li> <li> <p>Participants without underlying diseases compared to participants with underlying diseases such as genetic syndromes, lung disease, or immune deficiency. </p> </li> </ol> </p> <p>We planned to use the Chi<sup>2</sup> test to test for subgroup interactions in Review Manager 5 (<a href="./references#CD013864-bbs2-0110" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> </section> <section id="CD013864-sec-0047"> <h4 class="title">Sensitivity analysis</h4> <p>To assess the potential impact of missing data, we planned to perform two sensitivity analyses on the primary outcomes, as follows. </p> <p> <ol id="CD013864-list-0014"> <li> <p>‘Best‐worst‐case’ scenario: we assumed that all participants lost to follow‐up in the experimental group survived and had no serious adverse event. We assumed that all of those with missing outcomes in the control group did not survive and had a serious adverse event. </p> </li> <li> <p>'Worst‐best‐case’ scenario: we assumed that all participants lost to follow‐up in the experimental group did not survive and had a serious adverse event. We assumed that all participants lost to follow‐up in the control group survived and had no serious adverse event (<a href="./references#CD013864-bbs2-0079" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). </p> </li> </ol> </p> </section> <section id="CD013864-sec-0048"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created two summary of findings tables (<a href="./full#CD013864-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013864-tbl-0002">summary of findings Table 2</a>) reporting our primary and secondary outcomes<i>.</i> We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of a body of evidence as it relates to the studies which contribute data to the meta‐analyses for the prespecified outcomes (<a href="./references#CD013864-bbs2-0038" title="AtkinsD , BestD , BrissPA , EcclesM , Falck-YtterY , FlottorpS , et al, GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490.">Atkins 2004</a>). We used the methods and recommendations in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013864-bbs2-0070" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>), employing GRADEpro GDT software (<a href="./references#CD013864-bbs2-0062" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 23 January 2021. Hamilton (ON): McMaster University (developed by Evidence Prime), 2021. Available from gradepro.org.">GRADEpro GDT</a>). We justified all decisions to down‐ or upgrade the quality of the evidence using footnotes and made comments to aid the reader's understanding of the review where necessary. </p> <p>Had we performed a network meta‐analysis, we would also have used CINeMA to assess the certainty of a body of evidence (<a href="./references#CD013864-bbs2-0064" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed.)2008;336(7650):924-6.">Guyatt 2008</a>; <a href="./references#CD013864-bbs2-0066" title="GuyattGH , OxmanAD , SchünemannHJ , TugwellP , KnottnerusA . GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology2011;64(4):380-2.">Guyatt 2011b</a>; <a href="./references#CD013864-bbs2-0116" title="SchünemannHJ , BestD , VistG , OxmanAD , GRADE Working Group. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. Canadian Medical Association Journal2003;169(7):677-80.">Schünemann 2003</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013864-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013864-sec-0049"></div> <section id="CD013864-sec-0050"> <h3 class="title">Description of studies</h3> <p>For study details, see <a href="./references#CD013864-sec-0119" title="">Characteristics of included studies</a>, <a href="./references#CD013864-sec-0120" title="">Characteristics of excluded studies</a>, and <a href="./references#CD013864-sec-0121" title="">Characteristics of ongoing studies</a>. </p> <p>We based our assessment of the included trials on the recommendations provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, <a href="./references#CD013864-bbs2-0072" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>, and our protocol (<a href="./references#CD013864-bbs2-0143" title="KorangSK , NavaC , NygaardU , JakobsenJC . Antibiotics for hospital-acquired pneumonia in neonates and children. Cochrane Database of Systematic Reviews2021, Issue 1. Art. No: CD013864. [DOI: 10.1002/14651858.CD013864]">Korang 2021a</a>). </p> <section id="CD013864-sec-0051"> <h4 class="title">Results of the search</h4> <p>We searched seven databases (see <a href="#CD013864-sec-0029">Electronic searches</a>) and retrieved 1846 records. Our searches of the trial registers identified four further studies. Our searches of other resources identified no additional studies appearing to meet the inclusion criteria. Screening reference lists of the included publications revealed two potentially relevant studies. We therefore retrieved a total of 1852 records, which amounted to 1499 records after de‐duplication. We excluded 1466 records based on title and abstract, and obtained the full texts of the remaining 33 records. We excluded 28 studies (see <a href="./references#CD013864-sec-0120" title="">Characteristics of excluded studies</a>). We identified one ongoing trial that might include children with hospital‐acquired pneumonia (<a href="./references#CD013864-bbs2-0033" title="ShahrinL , Chisti MohammodJ , ShahidAS , RahmanAS , IslamMZ , AfrozeF , et al. Injectable amoxicillin versus injectable ampicillin plus gentamicin in the treatment of severe pneumonia in children aged 2 to 59 months: protocol for an open-label randomized controlled trial. JMIR Research Protocols2020;9(11):e17735. ">Shahrin 2020</a>). </p> <p>We included four trials reported in eight articles. Our screening process is illustrated in a PRISMA flow diagram (see <a href="#CD013864-fig-0001">Figure 1</a>). </p> </section> <section id="CD013864-sec-0052"> <h4 class="title">Included studies</h4> <p>Four trials met our inclusion criteria (<a href="./references#CD013864-bbs2-0001" title="BoshevaM , GujabidzeR , Károly É, NemethA , SaulayM , SmartJL , et al. A phase 3 randomized investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatric Infectious Disease Journal 2021 Jun 1 [Epub ahead of print]. [DOI: 10.1097/INF.0000000000003077]">Bosheva 2021</a>; <a href="./references#CD013864-bbs2-0002" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(Suppl 9):164-71. KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92. SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200. ">Jantausch 2003</a>; <a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a>; <a href="./references#CD013864-bbs2-0004" title="ShahidSK . Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. Annals of Tropical Medicine and Parasitology2008;102(1):63-71. ">Shahid 2008</a>). Four additional papers were included as secondary publications to <a href="./references#CD013864-bbs2-0002" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(Suppl 9):164-71. KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92. SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200. ">Jantausch 2003</a> (<a href="./references#CD013864-bbs2-0053" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. ">Deville 2003</a>; <a href="./references#CD013864-bbs2-0084" title="KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86.">Kaplan 2003</a>; <a href="./references#CD013864-bbs2-0096" title="MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92.">Meissner 2003</a>; <a href="./references#CD013864-bbs2-0113" title="SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200.">Saiman 2003</a>). For study details, see <a href="./references#CD013864-sec-0119" title="">Characteristics of included studies</a>. Three trials were multicentre trials and included 59 sites in the USA and Latin America (<a href="./references#CD013864-bbs2-0002" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(Suppl 9):164-71. KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92. SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200. ">Jantausch 2003</a>), 12 sites in Europe (<a href="./references#CD013864-bbs2-0001" title="BoshevaM , GujabidzeR , Károly É, NemethA , SaulayM , SmartJL , et al. A phase 3 randomized investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatric Infectious Disease Journal 2021 Jun 1 [Epub ahead of print]. [DOI: 10.1097/INF.0000000000003077]">Bosheva 2021</a>), 22 sites in Europe and South Africa (<a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a>), and one site in Malaysia (<a href="./references#CD013864-bbs2-0004" title="ShahidSK . Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. Annals of Tropical Medicine and Parasitology2008;102(1):63-71. ">Shahid 2008</a>). Three trials included children with different infections, of which a minor portion was hospital‐acquired pneumonia (<a href="./references#CD013864-bbs2-0001" title="BoshevaM , GujabidzeR , Károly É, NemethA , SaulayM , SmartJL , et al. A phase 3 randomized investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatric Infectious Disease Journal 2021 Jun 1 [Epub ahead of print]. [DOI: 10.1097/INF.0000000000003077]">Bosheva 2021</a>; <a href="./references#CD013864-bbs2-0002" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(Suppl 9):164-71. KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92. SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200. ">Jantausch 2003</a>; <a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a>). Two trials primarily included community‐acquired pneumonia, <a href="./references#CD013864-bbs2-0001" title="BoshevaM , GujabidzeR , Károly É, NemethA , SaulayM , SmartJL , et al. A phase 3 randomized investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatric Infectious Disease Journal 2021 Jun 1 [Epub ahead of print]. [DOI: 10.1097/INF.0000000000003077]">Bosheva 2021</a>, and hospitalised children with bacterial infections (<a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a>), hence the children with hospital‐acquired pneumonia constituted only subgroups of the total sample sizes. One trial included participants with late‐onset ventilator‐associated pneumonia only (<a href="./references#CD013864-bbs2-0004" title="ShahidSK . Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. Annals of Tropical Medicine and Parasitology2008;102(1):63-71. ">Shahid 2008</a>). </p> <section id="CD013864-sec-0053"> <h5 class="title">Participants</h5> <p>The four trials randomised a total of 84 participants. The studies included participants of the following age groups: </p> <p> <ol id="CD013864-list-0015"> <li> <p>under one year (<a href="./references#CD013864-bbs2-0004" title="ShahidSK . Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. Annals of Tropical Medicine and Parasitology2008;102(1):63-71. ">Shahid 2008</a>); </p> </li> <li> <p>birth to 12 years (<a href="./references#CD013864-bbs2-0002" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(Suppl 9):164-71. KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92. SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200. ">Jantausch 2003</a>); </p> </li> <li> <p>3 months to 12 years (<a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a>); </p> </li> <li> <p>3 months to 18 years (<a href="./references#CD013864-bbs2-0001" title="BoshevaM , GujabidzeR , Károly É, NemethA , SaulayM , SmartJL , et al. A phase 3 randomized investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatric Infectious Disease Journal 2021 Jun 1 [Epub ahead of print]. [DOI: 10.1097/INF.0000000000003077]">Bosheva 2021</a>). </p> </li> </ol> </p> </section> <section id="CD013864-sec-0054"> <h5 class="title">Interventions</h5> <p>The four trials compared four different antibiotic regimens, as follows:</p> <p> <ol id="CD013864-list-0016"> <li> <p>cefepime versus ceftazidime (<a href="./references#CD013864-bbs2-0004" title="ShahidSK . Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. Annals of Tropical Medicine and Parasitology2008;102(1):63-71. ">Shahid 2008</a>); </p> </li> <li> <p>linezolid versus vancomycin (<a href="./references#CD013864-bbs2-0002" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(Suppl 9):164-71. KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92. SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200. ">Jantausch 2003</a>); </p> </li> <li> <p>ceftobiprole versus standard of care (cephalosporin) (<a href="./references#CD013864-bbs2-0001" title="BoshevaM , GujabidzeR , Károly É, NemethA , SaulayM , SmartJL , et al. A phase 3 randomized investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatric Infectious Disease Journal 2021 Jun 1 [Epub ahead of print]. [DOI: 10.1097/INF.0000000000003077]">Bosheva 2021</a>); </p> </li> <li> <p>meropenem versus cefotaxime (<a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a>). </p> </li> </ol> </p> <p>One trial administered metronidazole in cases of mixed aerobic/anaerobic infection, but only for the control group (<a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a>). One trial described the use of vancomycin in the control group when MRSA was confirmed or suspected, and similarly amikacin, gentamicin, or tobramycin was administered in the control groups when infection by <i>P aeruginosa</i> was confirmed or suspected (<a href="./references#CD013864-bbs2-0001" title="BoshevaM , GujabidzeR , Károly É, NemethA , SaulayM , SmartJL , et al. A phase 3 randomized investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatric Infectious Disease Journal 2021 Jun 1 [Epub ahead of print]. [DOI: 10.1097/INF.0000000000003077]">Bosheva 2021</a>). </p> </section> <section id="CD013864-sec-0055"> <h5 class="title">Co‐interventions</h5> <p>One trial provided concomitant treatment in both groups with amikacin, vancomycin, gentamicin, or tobramycin for confirmed or suspected infection caused by <i>P aeruginosa</i>, which could be added at the discretion of the blinded investigator (<a href="./references#CD013864-bbs2-0001" title="BoshevaM , GujabidzeR , Károly É, NemethA , SaulayM , SmartJL , et al. A phase 3 randomized investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatric Infectious Disease Journal 2021 Jun 1 [Epub ahead of print]. [DOI: 10.1097/INF.0000000000003077]">Bosheva 2021</a>). The remaining trials did not report co‐interventions (<a href="./references#CD013864-bbs2-0002" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(Suppl 9):164-71. KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92. SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200. ">Jantausch 2003</a>; <a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a>; <a href="./references#CD013864-bbs2-0004" title="ShahidSK . Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. Annals of Tropical Medicine and Parasitology2008;102(1):63-71. ">Shahid 2008</a>). </p> </section> <section id="CD013864-sec-0056"> <h5 class="title">Outcomes</h5> <p>Only one trial reported sparse data on all‐cause mortality and serious adverse events (<a href="./references#CD013864-bbs2-0004" title="ShahidSK . Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. Annals of Tropical Medicine and Parasitology2008;102(1):63-71. ">Shahid 2008</a>). This trial did not report serious adverse events according to the ICH‐GCP, but reported the number of deaths in each group. Three trials reported treatment failure (<a href="./references#CD013864-bbs2-0002" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(Suppl 9):164-71. KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92. SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200. ">Jantausch 2003</a>; <a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a>; <a href="./references#CD013864-bbs2-0004" title="ShahidSK . Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. Annals of Tropical Medicine and Parasitology2008;102(1):63-71. ">Shahid 2008</a>). None of the included trials assessed health‐related quality of life, pneumonia‐related mortality, or non‐serious adverse events. </p> </section> <section id="CD013864-sec-0057"> <h5 class="title">Antibiotic resistance in included trials</h5> <p>One trial reported that resistance to study medications was not found in pathogens isolated at baseline in either group (<a href="./references#CD013864-bbs2-0002" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(Suppl 9):164-71. KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92. SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200. ">Jantausch 2003</a>). The remaining trials did not report on antibiotic resistance amongst the culture‐positive participants having hospital‐acquired pneumonia (<a href="./references#CD013864-bbs2-0001" title="BoshevaM , GujabidzeR , Károly É, NemethA , SaulayM , SmartJL , et al. A phase 3 randomized investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatric Infectious Disease Journal 2021 Jun 1 [Epub ahead of print]. [DOI: 10.1097/INF.0000000000003077]">Bosheva 2021</a>; <a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a>; <a href="./references#CD013864-bbs2-0004" title="ShahidSK . Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. Annals of Tropical Medicine and Parasitology2008;102(1):63-71. ">Shahid 2008</a>) </p> </section> </section> <section id="CD013864-sec-0058"> <h4 class="title">Excluded studies</h4> <p>We assessed 28 trials as potentially relevant upon review of the abstract, but that were later excluded after full‐text review. The reasons for exclusion were as follows. </p> <p> <ol id="CD013864-list-0017"> <li> <p>Wrong participant population, such as adults or participants that did not have hospital‐acquired pneumonia (25 trials) (<a href="./references#CD013864-bbs2-0005" title="AgweyuA , GatharaD , OliwaJ , MuingaN , EdwardsT , AllenE , et al. Oral amoxicillin versus benzyl penicillin for severe pneumonia among Kenyan children: a pragmatic randomized controlled noninferiority trial. Clinical Infectious Diseases2015;60(8):1216-24. ">Agweyu 2015</a>; <a href="./references#CD013864-bbs2-0006" title="AmonovaDS , IbadovaDN . Clinical and bacteriological efficiency of two modes of ceftazidim and aminkacin dosing in patients with ventilator-associated pneumonia. Likars'ka Sprava2011;1(2):110-7. ">Amonova 2011</a>; <a href="./references#CD013864-bbs2-0007" title="AwadSS , RodriguezAH , ChuangYC , MarjanekZ , PareigisAJ , ReisG , et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clinical Infectious Diseases2014;69(1):51-61. ">Awad 2014</a>; <a href="./references#CD013864-bbs2-0008" title="BarradasP , ZamithM , VideiraW , CardosaT , MarquesRA , AvilaR . Therapy of lower respiratory tract infections: a comparison of ceftriaxone and cefotaxime. Chemotherapy1989;35(Suppl 2):33-40. ">Barradas 1989</a>; <a href="./references#CD013864-bbs2-0009" title="BassettiD , CrucianiM , SolbiatiM , RubiniF , GandolaL , ValentiG , et al. Comparative efficacy of ceftriaxone versus ceftazidime in the treatment of nosocomial lower respiratory tract infections. Chemotherapy1991;37(5):371-5. ">Bassetti 1991</a>; <a href="./references#CD013864-bbs2-0010" title="BegueP , AstrucJ , FrancoisP , FloretD . Comparison of ceftriaxone and cefotaxime in severe pediatric bacterial infection: a multicentric study [Evaluation de la ceftriaxone et du cefotaxime dans l'infection bacterienne severe en pediatrie: etude muticentrique]. Medecine et Maladies Infectieuses1998;28(4):300-6. ">Begue 1998</a>; <a href="./references#CD013864-bbs2-0012" title="BhavnaniSM , RubinoCM , HammelJP , ForrestA , DartoisN , CooperCA , et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrobial Agents and Chemotherapy2012;56(2):1065-72. ">Bhavnani 2012</a>; <a href="./references#CD013864-bbs2-0013" title="ChaudharyM , ShrivastavaSM , VarugheseL , SehgalR . Efficacy and safety evaluation of fixed dose combination of cefepime and amikacin in comparison with cefepime alone in treatment of nosocomial pneumonia patients. Current Clinical Pharmacology2008;3(2):118-22. ">Chaudhary 2008</a>; <a href="./references#CD013864-bbs2-0014" title="ChuchalinAG , NovikovK , AvdeevSN , BelevskiĭAS . Effectiveness of ciprofloxacin in the treatment of hospital infections of the lower respiratory tract. Antibiotiki I Khimioterapiia1997;42(6):34-8. ">Chuchalin 1997</a>; <a href="./references#CD013864-bbs2-0015" title="ComettaA , BaumgartnerJD , LewD , ZimmerliW , PittetD , ChopartP , et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrobial Agents and Chemotherapy1994;38(6):1309-13. ">Cometta 1994</a>; <a href="./references#CD013864-bbs2-0016" title="DicksteinY , LeiboviciL , YahavD , Eliakim-RazN , DaikosGL , SkiadaA , et al. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. BMJ Open2016;6(4):e009956. ">Dickstein 2016</a>; <a href="./references#CD013864-bbs2-0018" title="Giamarellos-Bourboulis EvangelosJ , MylonaV , AntonopoulouA , TsangarisI , KoutelidakisI , MarioliA , et al. Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial. Journal of Antimicrobial Chemotherapy2014;69(4):1111-8. ">Giamarellos‐Bourboulis 2014</a>; <a href="./references#CD013864-bbs2-0019" title="GrudininaSA , ZubkovMM , KrotovaLA , Kurdiukova IuP , KutsenkoMA , MarininVF , et al. Comparison of linezolid and vancomycin in nosocomial pneumonia: results of the multicenter double-blind study. Antibiotiki I Khimioterapiia2002;47(1):12-7. ">Grudinina 2002</a>; <a href="./references#CD013864-bbs2-0020" title="IakovlevSV , DvoretskiiLI , ShakhovaTV . The clinical efficacy of ticarcillin/clavulanate in severe pneumonia. Antibiotiki I Khimioterapiia2000;45(3):30-4. ">Iakovlev 2000</a>; <a href="./references#CD013864-bbs2-0021" title="IakovlevSV , BeloborodovVB , SidorenkoSV , IakovlevVP , Grigor'evKB , EliseevaEV , et al. Multicentre study of comparative efficacy of meropenem and combined regimens for empirical antibacterial therapy of severe nosocomial infections: results of clinical and pharmacoeconomic analysis. Antibiotiki I Khimioterapiia2006;51(7):15-27. ">Iakovlev 2006</a>; <a href="./references#CD013864-bbs2-0022" title="JoshiM . Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Journal of Antimicrobial Chemotherapy1999;43(3):389-97. ">Joshi 1999</a>; <a href="./references#CD013864-bbs2-0023" title="KollefMH , ChastreJ , ClavelM , RestrepoMI , MichielsB , KanigaK , et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Critical Care2012;16(6):R218. ">Kollef 2012</a>; <a href="./references#CD013864-bbs2-0024" title="LacyMK , StryjewskiME , WangW , HardinTC , NogidB , LukeDR , et al. Telavancin hospital-acquired pneumonia trials: impact of gram-negative infections and inadequate gram-negative coverage on clinical efficacy and all-cause mortality. Clinical Infectious Diseases2015;Suppl 61:87-93. [DOI: 10.1093/cid/civ536]">Lacy 2015</a>; <a href="./references#CD013864-bbs2-0025" title="MohamedSS , DayemAM , SakrML , DwedarIA . The effect of administration of fosfomycin in the management of ventilator-associated pneumonia. Egyptian Journal of Chest Diseases and Tuberculosis2018;67(3):318. ">Mohamed 2018</a>; <a href="./references#CD013864-bbs2-0026" title="MuscedereJG , ShorrAF , JiangX , DayA , HeylandDK . The adequacy of timely empiric antibiotic therapy for ventilator-associated pneumonia: an important determinant of outcome. Journal of Critical Care2012;27(3):322.e7-e14. ">Muscedere 2012</a>; <a href="./references#CD013864-bbs2-0027" title="NassarYS , Saber-AyadM , ShashRY . Combined microbiological and clinical outcomes of short-term inhaled colistin adjunctive therapy in ventilator-associated pneumonia. Egyptian Journal of Chest Diseases and Tuberculosis2018;67(4):376-83. ">Nassar 2018</a>; <a href="./references#CD013864-bbs2-0028" title="NorrbySR , Finch RogerG , GlauserM . Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. Journal of Antimicrobial Chemotherapy1993;31(6):927-37. ">Norrby 1993</a>; <a href="./references#CD013864-bbs2-0030" title="RodloffA , LaubenthalHJ , BastianA ,  BestehornK ,  Büchele G,  Gaus W. Comparative study of the cost/effectiveness ratio of an initial therapy with imipenem/cilastatin in nosocomial pneumonia [Vergleichende untersuchung zum kosten-/effektivitäts-verhältnis einer initialen therapie mit imipenem/cilastatin bei der nosokomialen pneumonie]. Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie1996;31(3):172-80. ">Rodloff 1996</a>; <a href="./references#CD013864-bbs2-0031" title="StraneoG , ScarpazzaG . Efficacy and safety of clarithromycin versus josamycin in the treatment of hospitalized patients with bacterial pneumonia. Journal of International Medical Research1990;18(2):164-70. ">Straneo 1990</a>; <a href="./references#CD013864-bbs2-0032" title="TuckerH , WibleM , GandhiA , QuintanaA . Efficacy of intravenous tigecycline in patients with Acinetobacter complex infections: results from 14 Phase III and Phase IV clinical trials. Infection and Drug Resistance2017;10:401-17. ">Tucker 2017</a>). </p> </li> <li> <p>Not randomised (1 trial) (<a href="./references#CD013864-bbs2-0011" title="BermanSJ , FogartyCM , FabianT , MelnickD , LeskyW . Meropenem monotherapy for the treatment of hospital-acquired pneumonia: results of a multicenter trial. Journal of Chemotherapy2004;16(4):362-71. ">Berman 2004</a>). </p> </li> <li> <p>The same antibiotic assessed in the intervention and control groups (2 trials) (<a href="./references#CD013864-bbs2-0017" title="FatehiS , EshaghiH , SharifzadehM , MirrahimiB , QorbaniM , TanzifiP , et al. A randomized clinical trial evaluating the efficacy of colistin loading dose in critically ill children. Journal of Research in Pharmacy Practice2019;8(4):196-201. ">Fatehi 2019</a>; <a href="./references#CD013864-bbs2-0029" title="PatelAB , BangA , SinghM , ChelliahLR , MalikA , KhadseS , et al. A randomized controlled trial of hospital versus home based therapy with oral amoxicillin for severe pneumonia in children aged 3 – 59 months: The IndiaCLEN Severe Pneumonia Oral Therapy (ISPOT) Study. BMC Pediatrics2015;15:186. ">Patel 2015</a>). </p> </li> </ol> </p> <p>For details, see <a href="./references#CD013864-sec-0120" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD013864-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed all of the included trials as at overall high risk of bias (see <a href="#CD013864-fig-0002">Figure 2</a>; <a href="#CD013864-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD013864-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013864-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_n/nCD013864-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD013864-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013864-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_n/nCD013864-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD013864-sec-0060"> <h4 class="title">Allocation</h4> <p>Three trials used a computer‐generated assignment sequence resulting in 'low risk of bias' (<a href="./references#CD013864-bbs2-0001" title="BoshevaM , GujabidzeR , Károly É, NemethA , SaulayM , SmartJL , et al. A phase 3 randomized investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatric Infectious Disease Journal 2021 Jun 1 [Epub ahead of print]. [DOI: 10.1097/INF.0000000000003077]">Bosheva 2021</a>; <a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a>; <a href="./references#CD013864-bbs2-0004" title="ShahidSK . Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. Annals of Tropical Medicine and Parasitology2008;102(1):63-71. ">Shahid 2008</a>). One trial did not describe how allocation sequence generation was performed and was therefore judged as 'unclear risk of bias' (<a href="./references#CD013864-bbs2-0002" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(Suppl 9):164-71. KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92. SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200. ">Jantausch 2003</a>). </p> <p>None of the trials described allocation concealment, therefore we judged all four trials as 'unclear risk of bias' (<a href="./references#CD013864-bbs2-0001" title="BoshevaM , GujabidzeR , Károly É, NemethA , SaulayM , SmartJL , et al. A phase 3 randomized investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatric Infectious Disease Journal 2021 Jun 1 [Epub ahead of print]. [DOI: 10.1097/INF.0000000000003077]">Bosheva 2021</a>; <a href="./references#CD013864-bbs2-0002" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(Suppl 9):164-71. KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92. SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200. ">Jantausch 2003</a>; <a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a>; <a href="./references#CD013864-bbs2-0004" title="ShahidSK . Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. Annals of Tropical Medicine and Parasitology2008;102(1):63-71. ">Shahid 2008</a>). </p> </section> <section id="CD013864-sec-0061"> <h4 class="title">Blinding</h4> <p>Two trials were unblinded and were assessed as 'high risk of bias' in both domains (<a href="./references#CD013864-bbs2-0002" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(Suppl 9):164-71. KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92. SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200. ">Jantausch 2003</a>; <a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a>). One trial did not describe blinding and was assessed as 'unclear risk of bias' in both domains (<a href="./references#CD013864-bbs2-0004" title="ShahidSK . Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. Annals of Tropical Medicine and Parasitology2008;102(1):63-71. ">Shahid 2008</a>). The remaining trial blinded the investigators but not the treatment providers/participants, resulting in a judgement of 'low risk of bias' for blinding of outcome assessment and 'high risk of bias' for blinding of participants and personnel (<a href="./references#CD013864-bbs2-0001" title="BoshevaM , GujabidzeR , Károly É, NemethA , SaulayM , SmartJL , et al. A phase 3 randomized investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatric Infectious Disease Journal 2021 Jun 1 [Epub ahead of print]. [DOI: 10.1097/INF.0000000000003077]">Bosheva 2021</a>). </p> </section> <section id="CD013864-sec-0062"> <h4 class="title">Incomplete outcome data</h4> <p>Two trials had a high number of dropouts and were assessed as 'high risk of bias' (<a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a>; <a href="./references#CD013864-bbs2-0004" title="ShahidSK . Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. Annals of Tropical Medicine and Parasitology2008;102(1):63-71. ">Shahid 2008</a>). Two trials did not describe dropouts and were assessed as 'unclear risk of bias' (<a href="./references#CD013864-bbs2-0001" title="BoshevaM , GujabidzeR , Károly É, NemethA , SaulayM , SmartJL , et al. A phase 3 randomized investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatric Infectious Disease Journal 2021 Jun 1 [Epub ahead of print]. [DOI: 10.1097/INF.0000000000003077]">Bosheva 2021</a>; <a href="./references#CD013864-bbs2-0002" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(Suppl 9):164-71. KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92. SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200. ">Jantausch 2003</a>). </p> </section> <section id="CD013864-sec-0063"> <h4 class="title">Selective reporting</h4> <p>One trial reported both mortality and serious adverse events, resulting in a judgement of 'low risk of bias' (<a href="./references#CD013864-bbs2-0004" title="ShahidSK . Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. Annals of Tropical Medicine and Parasitology2008;102(1):63-71. ">Shahid 2008</a>). Three trials did not have a protocol, nor did they report mortality and serious adverse events, resulting in a judgement of 'unclear risk of bias' (<a href="./references#CD013864-bbs2-0001" title="BoshevaM , GujabidzeR , Károly É, NemethA , SaulayM , SmartJL , et al. A phase 3 randomized investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatric Infectious Disease Journal 2021 Jun 1 [Epub ahead of print]. [DOI: 10.1097/INF.0000000000003077]">Bosheva 2021</a>; <a href="./references#CD013864-bbs2-0002" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(Suppl 9):164-71. KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92. SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200. ">Jantausch 2003</a>; <a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a>). </p> </section> <section id="CD013864-sec-0064"> <h4 class="title">Other potential sources of bias</h4> <p>We found that three trials were funded by the pharmaceutical companies that produce the studied antibiotics (<a href="./references#CD013864-bbs2-0001" title="BoshevaM , GujabidzeR , Károly É, NemethA , SaulayM , SmartJL , et al. A phase 3 randomized investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatric Infectious Disease Journal 2021 Jun 1 [Epub ahead of print]. [DOI: 10.1097/INF.0000000000003077]">Bosheva 2021</a>; <a href="./references#CD013864-bbs2-0002" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(Suppl 9):164-71. KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92. SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200. ">Jantausch 2003</a>; <a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a>).  Amongst those, we found one trial to be at high risk of other bias due to for‐profit bias (<a href="./references#CD013864-bbs2-0001" title="BoshevaM , GujabidzeR , Károly É, NemethA , SaulayM , SmartJL , et al. A phase 3 randomized investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatric Infectious Disease Journal 2021 Jun 1 [Epub ahead of print]. [DOI: 10.1097/INF.0000000000003077]">Bosheva 2021</a>) as the pharmaceutical company had a major involvement in designing the study and in the acquisition of data, statistical analysis, and article preparation. The other two (<a href="./references#CD013864-bbs2-0002" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(Suppl 9):164-71. KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92. SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200. ">Jantausch 2003</a>; <a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a>) were funded and may be influenced by vested interests, but no involvement of the funders was described. We found no other potential sources of bias in the remaining trials (<a href="./references#CD013864-bbs2-0002" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(Suppl 9):164-71. KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92. SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200. ">Jantausch 2003</a>; <a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a>; <a href="./references#CD013864-bbs2-0004" title="ShahidSK . Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. Annals of Tropical Medicine and Parasitology2008;102(1):63-71. ">Shahid 2008</a>).  </p> </section> </section> <section id="CD013864-sec-0065"> <h3 class="title" id="CD013864-sec-0065">Effects of interventions</h3> <p>See: <a href="./full#CD013864-tbl-0001"><b>Summary of findings 1</b> Cefepime compared with ceftazidime for hospital‐acquired pneumonia in neonates and children</a>; <a href="./full#CD013864-tbl-0002"><b>Summary of findings 2</b> Linezolid compared with vancomycin for hospital‐acquired pneumonia in neonates and children</a> </p> <p>The four trials assessed different comparisons of antibiotic regimens, therefore we did not perform any meta‐analyses, trials sequential analyses, or subgroup analyses on any our outcomes. Of the two trials that had under 10 participants, one did not report our prespecified outcomes (<a href="./references#CD013864-bbs2-0001" title="BoshevaM , GujabidzeR , Károly É, NemethA , SaulayM , SmartJL , et al. A phase 3 randomized investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatric Infectious Disease Journal 2021 Jun 1 [Epub ahead of print]. [DOI: 10.1097/INF.0000000000003077]">Bosheva 2021</a>), and the other trial had an unclear comparison (<a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a>); we therefore decided not to include a summary of findings table for these two comparisons. </p> <p>Three trials compared two beta‐lactam antibiotics (<a href="./references#CD013864-bbs2-0001" title="BoshevaM , GujabidzeR , Károly É, NemethA , SaulayM , SmartJL , et al. A phase 3 randomized investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatric Infectious Disease Journal 2021 Jun 1 [Epub ahead of print]. [DOI: 10.1097/INF.0000000000003077]">Bosheva 2021</a>; <a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a>; <a href="./references#CD013864-bbs2-0004" title="ShahidSK . Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. Annals of Tropical Medicine and Parasitology2008;102(1):63-71. ">Shahid 2008</a>), and one trial compared a glycopeptide with an antibacterial agent (oxazolidinone) (<a href="./references#CD013864-bbs2-0002" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(Suppl 9):164-71. KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92. SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200. ">Jantausch 2003</a>). </p> <section id="CD013864-sec-0066"> <h4 class="title">Cefepime compared with ceftazidime for late‐onset ventilator‐associated pneumonia</h4> <section id="CD013864-sec-0067"> <h5 class="title">Primary outcomes</h5> <section id="CD013864-sec-0068"> <h6 class="title">All‐cause mortality</h6> <p>One trial showed that the effect of cefepime on mortality compared to ceftazidime is very uncertain (risk ratio (RR) 0.14, 95% confidence interval (CI) 0.01 to 2.55; 1 trial, 30 participants; very low‐certainty evidence; <a href="./references#CD013864-fig-0004" title="">Analysis 1.1</a>) (<a href="./references#CD013864-bbs2-0004" title="ShahidSK . Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. Annals of Tropical Medicine and Parasitology2008;102(1):63-71. ">Shahid 2008</a>). We calculated the optimal information size based on a relative risk reduction (RRR) of 20%, an alpha of 3.3%, a beta of 20%, and the observed incidence in the control group (15.4%) (<a href="./references#CD013864-bbs2-0067" title="GuyattGH , OxmanAD , KunzR ,  BrozekJ ,  Alonso-Coello P,  RindD , et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93.">Guyatt 2011c</a>; <a href="./references#CD013864-bbs2-0070" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>). Calculation of the optimal information size showed that we did not have sufficient information to confirm or reject that cefepime compared with ceftazidime reduced the risk of death by 20% or more. </p> <p>This outcome was assessed as high risk of bias (<a href="#CD013864-fig-0002">Figure 2</a>), and the certainty of the evidence was very low (<a href="./full#CD013864-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD013864-sec-0069"> <h6 class="title">Proportion of participants with one or more serious adverse events</h6> <p>One trial showed that the effect of cefepime on serious adverse events compared to ceftazidime is very uncertain (RR 0.14, 95% CI 0.01 to 2.55; 1 trial, 30 participants; very low‐certainty evidence; <a href="./references#CD013864-fig-0005" title="">Analysis 1.2</a>) (<a href="./references#CD013864-bbs2-0004" title="ShahidSK . Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. Annals of Tropical Medicine and Parasitology2008;102(1):63-71. ">Shahid 2008</a>). We calculated the optimal information size based on an RRR of 20%, an alpha of 3.3%, a beta of 20%, and the observed incidence in the control group (15.4%) (<a href="./references#CD013864-bbs2-0067" title="GuyattGH , OxmanAD , KunzR ,  BrozekJ ,  Alonso-Coello P,  RindD , et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93.">Guyatt 2011c</a>; <a href="./references#CD013864-bbs2-0070" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>). Calculation of the optimal information size showed that we did not have sufficient information to confirm or reject that cefepime versus ceftazidime reduced the risk of having a serious adverse event by 20% or more. </p> <p>This outcome was assessed as high risk of bias (<a href="#CD013864-fig-0002">Figure 2</a>), and the certainty of the evidence was very low (<a href="./full#CD013864-tbl-0001">summary of findings Table 1</a>). </p> </section> </section> <section id="CD013864-sec-0070"> <h5 class="title">Secondary outcomes</h5> <p><a href="./references#CD013864-bbs2-0004" title="ShahidSK . Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. Annals of Tropical Medicine and Parasitology2008;102(1):63-71. ">Shahid 2008</a> did not report health‐related quality of life, pneumonia‐related mortality, or non‐serious adverse events for participants with hospital‐acquired pneumonia. </p> <section id="CD013864-sec-0071"> <h6 class="title">Proportion of participants with treatment failure</h6> <p>One trial showed that the effect of cefepime on serious adverse events compared to ceftazidime is very uncertain (RR 0.50, 95% CI 0.15 to 1.64; 1 trial, 30 participants; very low‐certainty evidence; <a href="./references#CD013864-fig-0006" title="">Analysis 1.3</a>) (<a href="./references#CD013864-bbs2-0004" title="ShahidSK . Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. Annals of Tropical Medicine and Parasitology2008;102(1):63-71. ">Shahid 2008</a>). We calculated the optimal information size based on an RRR of 20%, an alpha of 3.3%, a beta of 20%, and the observed incidence in the control group (40%) (<a href="./references#CD013864-bbs2-0067" title="GuyattGH , OxmanAD , KunzR ,  BrozekJ ,  Alonso-Coello P,  RindD , et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93.">Guyatt 2011c</a>; <a href="./references#CD013864-bbs2-0070" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>). Calculation of the optimal information size showed that we did not sufficient information to confirm or reject that cefepime versus ceftazidime reduced the risk of having treatment failure by 20% or more. </p> <p>This outcome was assessed as high risk of bias (<a href="#CD013864-fig-0002">Figure 2</a>), and the certainty of the evidence was very low (<a href="./full#CD013864-tbl-0001">summary of findings Table 1</a>). </p> <p>As we only included one trial in this comparison, we did not perform a subgroup analysis, sensitivity analysis, or funnel plot. </p> </section> </section> </section> <section id="CD013864-sec-0072"> <h4 class="title">Linezolid compared with vancomycin for hospital‐acquired pneumonia</h4> <section id="CD013864-sec-0073"> <h5 class="title">Primary outcomes</h5> <p><a href="./references#CD013864-bbs2-0002" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(Suppl 9):164-71. KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92. SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200. ">Jantausch 2003</a> did not report all‐cause mortality or the proportion of participants with one or more serious adverse events for hospital‐acquired pneumonia. </p> </section> <section id="CD013864-sec-0074"> <h5 class="title">Secondary outcomes</h5> <p><a href="./references#CD013864-bbs2-0002" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(Suppl 9):164-71. KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92. SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200. ">Jantausch 2003</a> did not report health‐related quality of life, pneumonia‐related mortality, or non‐serious adverse events for participants with hospital‐acquired pneumonia. </p> <section id="CD013864-sec-0075"> <h6 class="title">Proportion of participants with treatment failure</h6> <p>One trial showed that the effect of linezolid on treatment failure compared to vancomycin is very uncertain (RR 2.05, 95% CI 0.49 to 8.63; 1 trial, 32 participants; very low‐certainty evidence; <a href="./references#CD013864-fig-0007" title="">Analysis 2.1</a>) (<a href="./references#CD013864-bbs2-0002" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal2003;22(Suppl 9):158-63. JantauschBA , DevilleJ , AdlerS , MorfinMR , LopezP , Edge-PadburyB , et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatric Infectious Disease Journal2003;22(Suppl 9):164-71. KaplanSL , DevilleJG , YogevR , MorfinMR , WuE , AdlerS , et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal2003;22(8):677-86. MeissnerHC , TownsendT , WenmanW , KaplanSL , MorfinMR , Edge-PadburyB , et al. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal2003;22(Suppl 9):186-92. SaimanL , GoldfarbJ , KaplanSA , WibleK , Edge-PadburyB , Naberhuis-StehouwerS , et al. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal2003;22(Suppl 9):193-200. ">Jantausch 2003</a>). We defined treatment failure as participants not being clinically cured. We calculated the optimal information size based on an RRR of 20%, an alpha of 3.3%, a beta of 20%, and the observed incidence in the control group (15.4%) (<a href="./references#CD013864-bbs2-0067" title="GuyattGH , OxmanAD , KunzR ,  BrozekJ ,  Alonso-Coello P,  RindD , et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93.">Guyatt 2011c</a>; <a href="./references#CD013864-bbs2-0070" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>). Calculation of the optimal information size showed that we did not have sufficient information to confirm or reject that linezolid versus vancomycin reduced the risk of having treatment failure by 20% or more. </p> <p>This outcome was assessed as high risk of bias (<a href="#CD013864-fig-0002">Figure 2</a>), and the certainty of the evidence was very low (<a href="./full#CD013864-tbl-0002">summary of findings Table 2</a>). </p> <p>As we only included one trial in this comparison, we did not perform a subgroup analysis, sensitivity analysis, or funnel plot. </p> </section> </section> </section> <section id="CD013864-sec-0076"> <h4 class="title">Ceftobiprole compared with standard of care (cephalosporin) for hospital‐acquired pneumonia </h4> <section id="CD013864-sec-0077"> <h5 class="title">Primary outcomes</h5> <p><a href="./references#CD013864-bbs2-0001" title="BoshevaM , GujabidzeR , Károly É, NemethA , SaulayM , SmartJL , et al. A phase 3 randomized investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatric Infectious Disease Journal 2021 Jun 1 [Epub ahead of print]. [DOI: 10.1097/INF.0000000000003077]">Bosheva 2021</a> did not report all‐cause mortality or the proportion of participants with one or more serious adverse events for hospital‐acquired pneumonia. </p> </section> <section id="CD013864-sec-0078"> <h5 class="title">Secondary outcomes</h5> <p><a href="./references#CD013864-bbs2-0001" title="BoshevaM , GujabidzeR , Károly É, NemethA , SaulayM , SmartJL , et al. A phase 3 randomized investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatric Infectious Disease Journal 2021 Jun 1 [Epub ahead of print]. [DOI: 10.1097/INF.0000000000003077]">Bosheva 2021</a> did not report health‐related quality of life, pneumonia‐related mortality, the proportion of participants with one or more non‐serious adverse events, or the proportion of participants with treatment failure for hospital‐acquired pneumonia. </p> <p>As we only included one trial in this comparison, we did not perform a subgroup analysis, sensitivity analysis, or funnel plot. </p> </section> </section> <section id="CD013864-sec-0079"> <h4 class="title">Meropenem compared with cefotaxime for hospital‐acquired pneumonia</h4> <section id="CD013864-sec-0080"> <h5 class="title">Primary outcomes</h5> <p><a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a> did not report all‐cause mortality or the proportion of participants with one or more serious adverse events for hospital‐acquired pneumonia. </p> </section> <section id="CD013864-sec-0081"> <h5 class="title">Secondary outcomes</h5> <p><a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a> did not report health‐related quality of life, pneumonia‐related mortality, or non‐serious adverse events for participants with hospital‐acquired pneumonia. </p> <section id="CD013864-sec-0082"> <h6 class="title">Proportion of participants with treatment failure</h6> <p>One trial showed that the effect of meropenem on treatment failure compared to cefotaxime is very uncertain (RR 1.80, 95% CI 0.10 to 31.52; 1 trial, 6 participants; very low‐certainty evidence; <a href="./references#CD013864-fig-0008" title="">Analysis 3.1</a>) (<a href="./references#CD013864-bbs2-0003" title="SchulerD . Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Journal of Antimicrobial Chemotherapy1995;36(Suppl A):99-108. ">Schuler 1995</a>). We defined treatment failure as participants not being clinically cured. It was not possible to calculate the optimal information size, as we did not observe any incidence in the control group (<a href="./references#CD013864-bbs2-0067" title="GuyattGH , OxmanAD , KunzR ,  BrozekJ ,  Alonso-Coello P,  RindD , et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93.">Guyatt 2011c</a>; <a href="./references#CD013864-bbs2-0070" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>). However, as the trial included only six participants, it is fair to assume that there was insufficient information to confirm or reject that meropenem versus cefotaxime reduced the risk of having treatment failure by 20% or more. </p> <p>This outcome was assessed as high risk of bias (<a href="#CD013864-fig-0002">Figure 2</a>), and the certainty of the evidence was very low. </p> <p>As we only included one trial in this comparison, we did not perform any subgroup analysis, sensitivity analysis, or funnel plot. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013864-sec-0083" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013864-sec-0083"></div> <section id="CD013864-sec-0084"> <h3 class="title" id="CD013864-sec-0084">Summary of main results</h3> <p>We included four trials randomising a total of 84 participants. We assessed all trials as having high risk of bias. </p> <p>We did not conduct any meta‐analyses as the included trials all compared different antibiotic regimens. None of the comparisons reached the optimal information size (<a href="./full#CD013864-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013864-tbl-0002">summary of findings Table 2</a>). </p> <p>Where outcomes were reported, the certainty of the evidence was very low for each of the comparisons. We were unable to draw any meaningful conclusions from the numerical results. None of the included trials assessed health‐related quality of life, pneumonia‐related mortality, or non‐serious adverse events. </p> </section> <section id="CD013864-sec-0085"> <h3 class="title" id="CD013864-sec-0085">Overall completeness and applicability of evidence</h3> <p>The relative beneficial and harmful effects of different antibiotic regimens remain unclear due to a lack of well‐powered trials and high risk of systematic errors. The current evidence is insufficient to support any antibiotic regimen being superior to another. Large randomised clinical trials assessing different antibiotic regimens for hospital‐acquired pneumonia in children and neonates are warranted. </p> </section> <section id="CD013864-sec-0086"> <h3 class="title" id="CD013864-sec-0086">Quality of the evidence</h3> <section id="CD013864-sec-0087"> <h4 class="title">Heterogeneity</h4> <p>We did not perform a meta‐analysis, therefore we did not assess heterogeneity.</p> </section> <section id="CD013864-sec-0088"> <h4 class="title">Risk of systematic error ('bias')</h4> <p>All of the included trials were at high risk of bias.</p> <p>It was not possible to assess publication bias, as only four trials were included in the review. </p> </section> <section id="CD013864-sec-0089"> <h4 class="title">Risk of random error ('play of chance')</h4> <p>None of the trial results reached the optimal information size. It was not possible to perform trial sequential analysis, as we performed no meta‐analysis. </p> </section> <section id="CD013864-sec-0090"> <h4 class="title">GRADE</h4> <p>We assessed the certainty of the evidence for each of the outcomes using the GRADE approach (<a href="./full#CD013864-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013864-tbl-0002">summary of findings Table 2</a>). The evidence for each reported outcome was of very low certainty. The rationale for the GRADE assessment is given in footnotes (<a href="./full#CD013864-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013864-tbl-0002">summary of findings Table 2</a>). </p> </section> </section> <section id="CD013864-sec-0091"> <h3 class="title" id="CD013864-sec-0091">Potential biases in the review process</h3> <p>The main limitation of this review is the low number of randomised participants, and the very low certainty of the available evidence. A further limitation is that we could not perform a meta‐analysis, as none of the trials compared similar antibiotics. </p> <p>There might also be a difference between the pathogens and their antibiotic susceptibility in different countries. The optimal antibiotic regimen will therefore vary according to country and local risks of antibiotic resistance. The number of included trials was insufficient to confirm or reject this presumption. </p> <p>The lack of a gold standard for the diagnosis of hospital‐acquired pneumonia could result in clinical heterogeneity between studies. Some participants may have had an unrecognised viral aetiology of hospital‐acquired pneumonia. Although these cases of viral infection must be assumed to be equally distributed in the intervention groups, they might lead to an underestimation of the differences between different antibiotic regimens. </p> </section> <section id="CD013864-sec-0092"> <h3 class="title" id="CD013864-sec-0092">Agreements and disagreements with other studies or reviews</h3> <p>Although hospital‐acquired pneumonia is one of the most common nosocomial infections amongst the paediatric population, we are not aware of any other reviews assessing the effects of different antibiotic regimens in paediatric patients with hospital‐acquired pneumonia. </p> <p>In the latest review conducted by the National Institute for Health and Care Excellence to develop the therapeutic guideline for hospital‐acquired pneumonia (<a href="./references#CD013864-bbs2-0102" title="National Institute for Health and Care Excellence. Pneumonia (hospital-acquired): antimicrobial prescribing guideline. www.nice.org.uk/guidance/ng139 (accessed prior to 21 October 2021).">NICE 2019</a>), studies with a mixed population of hospital‐acquired pneumonia and community‐acquired pneumonia were excluded, unless ≥ 75% were a hospital‐acquired pneumonia population. Moreover, <a href="./references#CD013864-bbs2-0102" title="National Institute for Health and Care Excellence. Pneumonia (hospital-acquired): antimicrobial prescribing guideline. www.nice.org.uk/guidance/ng139 (accessed prior to 21 October 2021).">NICE 2019</a> excluded studies with a mixed population of ventilator‐ and non‐ventilator‐associated pneumonia where data could not be analysed separately. As such, no studies involving children were identified and included, even if they were recognised as a subgroup of interest in the study protocol. Instead, the authors decided to make recommendations for paediatric therapy on the basis of higher‐quality evidence on adults. </p> <p>Overall, whilst including six randomised clinical trials and one post hoc analysis, the <a href="./references#CD013864-bbs2-0102" title="National Institute for Health and Care Excellence. Pneumonia (hospital-acquired): antimicrobial prescribing guideline. www.nice.org.uk/guidance/ng139 (accessed prior to 21 October 2021).">NICE 2019</a> authors did not find any difference in their analysis of the effectiveness of antibiotic regimens in adults (<a href="./references#CD013864-bbs2-0102" title="National Institute for Health and Care Excellence. Pneumonia (hospital-acquired): antimicrobial prescribing guideline. www.nice.org.uk/guidance/ng139 (accessed prior to 21 October 2021).">NICE 2019</a>). Likewise, they did not find any statistical difference in adverse effects between antibiotics or classes of antibiotics in people with hospital‐acquired pneumonia. </p> <p>Although there are similarities between children and adults with hospital‐acquired pneumonia (e.g. pathogenesis), evidence from adult studies cannot be transmitted to treatment regimens in children with certainty. The spectrum of responsible bacteria may differ, as colonisation in the pharynx and trachea varies, particularly in young children, who are less commonly colonised with <i>S aureus</i> , <i>P aeruginosa</i>, and MDR pathogens, compared to adults (<a href="./references#CD013864-bbs2-0078" title="JainS , WilliamsDJ , ArnoldSR , AmpofoK , BramleyAM , ReedC , et al. Community-acquired pneumonia requiring hospitalization among U.S. children. New England Medical Journal2015;372(9):835-45.">Jain 2015</a>). Furthermore, antibiotic pharmacokinetics vary between adults and children (<a href="./references#CD013864-bbs2-0057" title="FernandezE , PerezR , HernandezAH , PilarT , ArtetaMA , RamosJT . Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics2011;3(1):53-72.">Fernandez 2011</a>; <a href="./references#CD013864-bbs2-0124" title="StephensonT . How children's responses to drugs differ from adults. British Journal of Clinical Pharmacology2005;59(6):670-3.">Stephenson 2005</a>), and children have less frequent underlying lung diseases and known risk factors such as chronic lung disease and chronic renal failure, which may influence the severity and treatment response (<a href="./references#CD013864-bbs2-0120" title="SopenaN , HerasE , CasasI , BechiniJ , GuaschI , Pedro-BotetML , et al. Risk factors for hospital-acquired pneumonia outside the intensive care unit: case-control study. American Journal of Infection Control2014;42(1):38-42.">Sopena 2014</a>). Choice of antibiotics, as well as dosing and treatment duration, should thus be evaluated in children with hospital‐acquired pneumonia. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013864-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/urn:x-wiley:14651858:media:CD013864:CD013864-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD013864-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_n/nCD013864-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_t/tCD013864-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/full#CD013864-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_n/nCD013864-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013864-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/urn:x-wiley:14651858:media:CD013864:CD013864-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013864-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_n/nCD013864-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_t/tCD013864-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/full#CD013864-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_n/nCD013864-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013864-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/urn:x-wiley:14651858:media:CD013864:CD013864-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013864-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_n/nCD013864-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_t/tCD013864-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/full#CD013864-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_n/nCD013864-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013864-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/urn:x-wiley:14651858:media:CD013864:CD013864-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cefepime compared with ceftazidime, Outcome 1: All‐cause mortality" data-id="CD013864-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_n/nCD013864-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_t/tCD013864-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Cefepime compared with ceftazidime, Outcome 1: All‐cause mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/references#CD013864-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_n/nCD013864-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013864-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/urn:x-wiley:14651858:media:CD013864:CD013864-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cefepime compared with ceftazidime, Outcome 2: Serious adverse events" data-id="CD013864-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_n/nCD013864-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_t/tCD013864-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Cefepime compared with ceftazidime, Outcome 2: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/references#CD013864-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_n/nCD013864-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013864-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/urn:x-wiley:14651858:media:CD013864:CD013864-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cefepime compared with ceftazidime, Outcome 3: Treatment failure" data-id="CD013864-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_n/nCD013864-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_t/tCD013864-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Cefepime compared with ceftazidime, Outcome 3: Treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/references#CD013864-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_n/nCD013864-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013864-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/urn:x-wiley:14651858:media:CD013864:CD013864-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Linezolid compared with vancomycin, Outcome 1: Treatment failure" data-id="CD013864-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_n/nCD013864-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_t/tCD013864-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Linezolid compared with vancomycin, Outcome 1: Treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/references#CD013864-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_n/nCD013864-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013864-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/urn:x-wiley:14651858:media:CD013864:CD013864-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Meropenem compared with cefotaxime, Outcome 1: Treatment failure" data-id="CD013864-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_n/nCD013864-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_t/tCD013864-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Meropenem compared with cefotaxime, Outcome 1: Treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/references#CD013864-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/media/CDSR/CD013864/image_n/nCD013864-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013864-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Cefepime compared with ceftazidime for hospital‐acquired pneumonia in neonates and children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cefepime compared with ceftazidime for hospital‐acquired pneumonia in neonates and children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates and children with hospital‐acquired pneumonia </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> cefepime </p> <p><b>Comparison:</b> ceftazidime </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ceftazidime</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Cefepime</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Maximum follow‐up</p> <p>(Time point was not described.)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b><br/>(2 to 510) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.14</b> (0.01 to 2.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 3262 (RR 0.80, α 0.033, β 0.20, Pc 20%)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Maximum follow‐up</p> <p>(Time point was not described.)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b><br/>(2 to 510) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.14</b> (0.01 to 2.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 3262 (RR 0.80, α 0.033, β 0.20, Pc 20%)</p> <p>Serious adverse events were deaths.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>Maximum follow‐up</p> <p>(Time point was not described.)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b><br/>(60 to 656) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b> (0.15 to 1.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 1272 (RR 0.80, α 0.033, β 0.20, Pc 40%)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p>Maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonia‐related mortality</b> </p> <p>Maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐serious adverse events</b> </p> <p>Maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OIS</b> : optimal information size; <b>RR:</b> risk ratio; <b>Pc:</b> percentage in control group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by 1 level for study limitations due to serious risk of bias, and two levels for imprecision due to very small information size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Cefepime compared with ceftazidime for hospital‐acquired pneumonia in neonates and children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/full#CD013864-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013864-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Linezolid compared with vancomycin for hospital‐acquired pneumonia in neonates and children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Linezolid compared with vancomycin for hospital‐acquired pneumonia in neonates and children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates and children with hospital‐acquired pneumonia </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> linezolid </p> <p><b>Comparison:</b> vancomycin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vancomycin</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Linezolid</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Maximum follow‐up</p> <p>(up to 35 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Maximum follow‐up</p> <p>(up to 35 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>Maximum follow‐up</p> <p>(up to 35 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>154 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>315 per 1000</b><br/>(75 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.05</b> (0.49 to 8.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OIS: 4438 (RR 0.80, α 0.033, β 0.20, Pc 15.4%)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p>Maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonia‐related mortality</b> </p> <p>Maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐serious adverse events</b> </p> <p>Maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OIS</b> : optimal information size; <b>RR:</b> risk ratio; <b>Pc:</b> percentage in control group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by 1 level for study limitations due to serious risk of bias, and 2 levels for imprecision due to very small information size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Linezolid compared with vancomycin for hospital‐acquired pneumonia in neonates and children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/full#CD013864-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013864-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Cefepime compared with ceftazidime</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.15, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Cefepime compared with ceftazidime</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/references#CD013864-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013864-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Linezolid compared with vancomycin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [0.49, 8.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Linezolid compared with vancomycin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/references#CD013864-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013864-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Meropenem compared with cefotaxime</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.10, 31.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Meropenem compared with cefotaxime</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013864.pub2/references#CD013864-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013864.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013864-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013864-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013864-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013864-note-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD013864-note-0011">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD013864-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013864-note-0015">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD013864-note-0008">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD013864-note-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013864-note-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013864-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013864\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013864\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013864\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013864\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013864\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013864\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013864\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013864\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013864\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013864\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013864\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013864\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013864\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013864\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013864\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013864\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013864\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013864\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=bzu3XIhG&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013864.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013864.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013864.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013864.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013864.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727640763"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013864.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727640767"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013864.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eb103fd1c936d',t:'MTc0MDcyNzY0MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 